

National Pharmaceutical Pricing Authority

Subject: Minutes of the 59th meeting of the Multidisciplinary Committee of Experts held on 08.05.2024 at 03:00 PM.

59th meeting of the "Multidisciplinary Committee of Experts" was held on 08.05.2024 at 03:00 PM under the convenorship of Shri Sanjay Kumar, Advisor (Cost). The following members attended the meeting: -

1. Shri Ranga Chandrashekar, Deputy Drugs Controller, CDSCO
2. Dr. J. J. Cherian, Scientist-E (Med), ICMR through Video Conferencing
3. Dr. Rakesh Kr. Singh, Associate Professor, NIPER Raebareli through Video Conferencing.
4. Dr. Y.K. Gupta, Principal Scientific Advisor (Projects), THSTI-DBT, GoI&Ex HoD, Pharmacology & Dean (Academics) AIIMS, New-Delhi – Co-Opted Member
5. Dr. Jai Prakash, Sr. Principal Scientific Officer, Indian Pharmacopoeia Commission- Co-opted member through Video Conferencing

The following officers of NPPA attended and presented the cases before the Committee

- a. Ms. Rashmi Tahiliani, Director (Pricing)
- b. Shri Mahaveer Saini, Deputy Director (Pricing)
- c. Ms. Yuvika Panwar, Assistant Director (Pricing)

Agenda Item No. 1: Retail price fixation under Para 5 of DPCO, 2013 – Each film coated bilayer tablet contains: Linagliptin + Dapagliflozin Propanediol Monohydrate eq to Dapagliflozin + Metformin Hydrochloride (as sustained release form) IP

1.1 The Committee noted that application for price fixation of the subject FDC has not been received earlier by NPPA. Further, the market data of the same is not available in the Pharmatrac database. Hence, the same is being placed before the MDC.

1.2 The proposed pricing methodology is in line with methodology adopted since 51st MDC held on 24.05.2023 for price fixation of FDCs containing three molecules of which one or more were off-patented. It is further mentioned that while working the different options, prices of only those FDCs were considered wherein one of the molecules is a scheduled drug, as this constitutes a new drug as per DPCO 2013 and price of other component was added. Hence, though the price of FDC which was not containing scheduled component, could be available in the Pharmatrac database, it was not considered for working out the different options.

1.3 The Committee deliberated upon the matter in detail and recommended as follows:

(i) Agenda Item No. 1 (a): Retail price fixation under Para 5 of DPCO, 2013 – Each film coated bilayer tablet contains: Linagliptin IP 5mg + Dapagliflozin Propanediol Monohydrate eq to Dapagliflozin 10mg + Metformin Hydrochloride (as sustained release form) IP 1000mg for M/s Theon Pharmaceuticals Ltd (Manufacturer) & M/s Alkem Laboratories Ltd. (Marketer) (F. No. 3908) at Rs. 20.78 per tablet excluding GST.

1. The committee deliberated on the matter and recommended retail price on the lines of DPCO amendment vide S.O. No. 2165(E) dated 11.05.2023 as below:

1	Manufacturer Name	M/s Theon Pharmaceuticals Ltd
2	Marketer Name	M/s Alkem Laboratories Ltd. (Applicant)
3	Date of Application	15.03.2024
4	Patented Component I	Linagliptin
5	Patent Holder	M/s Boehringer Ingelheim
6	License Holder	M/s Lupin LTD
7	Date of Patent Expiry	21.02.2022
8	Patented Component II	Dapagliflozin
9	Patent Holder	M/s Astra Zeneca
10	License Holder	M/s Sun Pharma and M/s Abbott Healthcare
11	Date of Patent Expiry	02.10.2020

Calculation of Retail Price

S.N.	Particulars	Data Month	Linagliptin (5mg) + Metformin 1000mg)	Dapagliflozin (10mg) + Metformin 1000mg)
A.	Retail price of FDC excluding Patent & License Holder	August 2023	11.52	11.79
B.	Other Component excluding Patent & License Holder	August 2023	12.03	11.24
			Dapagliflozin (10mg)	Linagliptin (5mg)
C.	Total		23.55	23.03
D.	Less: 20% of lower of A&B		2.30	2.25
E.	Calculated Price of applied FDC		21.25	20.78
F.	Claimed Price		25.89	25.89
G.	Recommended Price (Lower of worked out and claimed price) per tablet			20.78

(ii) **Agenda Item No. 1(b):** Retail price fixation under Para 5 of DPCO, 2013 – Each film coated bilayer tablet contains: Linagliptin IP 5mg + Dapagliflozin Propanediol Monohydrate eq to Dapagliflozin 10mg + Metformin Hydrochloride (as sustained release form) IP 1000mg for M/s Theon Pharmaceuticals Ltd (Manufacturer) & M/s Torrent Pharmaceuticals Ltd. (Marketer) (F. No. 3906) at Rs. 19.00 per tablet excluding GST.

1. The committee deliberated on the matter and recommended retail price on the lines of DPCO amendment vide S.O. No. 2165(E) dated 11.05.2023 as below:

1	Manufacturer Name	M/s Theon Pharmaceuticals Ltd
2	Marketer Name	M/s Torrent Pharmaceuticals Ltd. (Applicant)
3	Date of Application	14.03.2024
4	Patented Component I	Linagliptin
5	Patent Holder	M/s Boehringer Ingelheim
6	License Holder	M/s Lupin LTD
7	Date of Patent Expiry	21.02.2022
8	Patented Component II	Dapagliflozin
9	Patent Holder	M/s Astra Zeneca
10	License Holder	M/s Sun Pharma and M/s Abbott Healthcare
11	Date of Patent Expiry	02.10.2020

Calculation of Retail Price

S.N.	Particulars	Data Month	Linagliptin (5mg) + Metformin 1000mg)	Dapagliflozin (10mg) + Metformin 1000mg)
A.	Retail price of FDC excluding Patent & License Holder	August 23	11.52	11.79
B.	Other Component excluding Patent & License Holder	August 23	12.03 Dapagliflozin (10mg)	11.24 Linagliptin (5mg)
C.	Total		23.55	23.03
D.	Less: 20% of lower of A&B		2.30	2.25
E.	Calculated Price of applied FDC		21.25	20.78
F.	Claimed Price		19.00	19.00
G.	Recommended Price (Lower of worked out and claimed price) per tablet			19.00

(iii) **Agenda Item No. 1(c):** Retail price fixation under Para 5 of DPCO, 2013 – Each film coated bilayer tablet contains: Linagliptin IP 5mg + Dapagliflozin Propanediol Monohydrate eq to Dapagliflozin 10mg + Metformin Hydrochloride (as sustained release form) IP 1000mg for M/s Theon Pharmaceuticals Ltd (Manufacturer) & M/s Zydus Healthcare Ltd. (Marketer) (F. No. 3909) at Rs. 20.78 per tablet excluding GST.

1. The committee deliberated on the matter and recommended retail price on the lines of DPCO amendment vide S.O. No. 2165(E) dated 11.05.2023 as below:

1	Manufacturer Name	M/s Theon Pharmaceuticals Ltd
2	Marketer Name	M/s Zydus Healthcare Ltd. (Applicant)
3	Date of Application	15.03.2024
4	Patented Component I	Linagliptin
5	Patent Holder	M/s Boehringer Ingelheim
6	License Holder	M/s Lupin LTD
7	Date of Patent Expiry	21.02.2022
8	Patented Component II	Dapagliflozin
9	Patent Holder	M/s Astra Zeneca
10	License Holder	M/s Sun Pharma and M/s Abbott Healthcare
11	Date of Patent Expiry	02.10.2020

Calculation of Retail Price

S.N.	Particulars	Data Month	Linagliptin (5mg) + Metformin 1000mg)	Dapagliflozin (10mg) + Metformin 1000mg)
A.	Retail price of FDC excluding Patent & License Holder	August 23	11.52	11.79
B.	Other Component excluding Patent & License Holder	August 23	12.03	11.24
			Dapagliflozin (10mg)	Linagliptin (5mg)
C.	Total		23.55	23.03
D.	Less: 20% of lower of A&B		2.30	2.25
E.	Calculated Price of applied FDC		21.25	20.78
F.	Claimed Price		55.00	55.00
G.	Recommended Price (Lower of worked out and claimed price) per tablet			20.78

(iv) **Agenda Item No. 1(d):** Retail price fixation under Para 5 of DPCO, 2013 – Each film coated bilayer tablet contains: Linagliptin IP 5mg + Dapagliflozin Propanediol Monohydrate eq to Dapagliflozin 10mg + Metformin Hydrochloride (as sustained release form) IP 1000mg for M/s Theon Pharmaceuticals Ltd (Manufacturer) & M/s Micro Labs Ltd. (Marketer) (F. No. 3926) at Rs. 15.89 per tablet excluding GST.

1. The committee deliberated on the matter and recommended retail price on the lines of DPCO amendment vide S.O. No. 2165(E) dated 11.05.2023 as below:

1	Manufacturer Name	M/s Theon Pharmaceuticals Ltd
2	Marketer Name	M/s Micro Labs Ltd. (Applicant)
3	Date of Application	23.03.2024
4	Patented Component I	Linagliptin
5	Patent Holder	M/s Boehringer Ingelheim
6	License Holder	M/s Lupin LTD
7	Date of Patent Expiry	21.02.2022
8	Patented Component II	Dapagliflozin
9	Patent Holder	M/s Astra Zeneca
10	License Holder	M/s Sun Pharma and M/s Abbott Healthcare
11	Date of Patent Expiry	02.10.2020

Calculation of Retail Price

S.N.	Particulars	Data Month	Linagliptin (5mg) + Metformin 1000mg)	Dapagliflozin (10mg) + Metformin 1000mg)
A.	Retail price of FDC excluding Patent & License Holder	August 23	11.52	11.79
B.	Other Component excluding Patent & License Holder	August 23	12.03 Dapagliflozin (10mg)	11.24 Linagliptin (5mg)
C.	Total		23.55	23.03
D.	Less: 20% of lower of A&B		2.30	2.25
E.	Calculated Price of applied FDC		21.25	20.78
F.	Claimed Price		15.89	15.89
G.	Recommended Price (Lower of worked out and claimed price) per tablet			15.89

(v) **Agenda Item No. 1(e):** Retail price fixation under Para 5 of DPCO, 2013 – Each film coated bilayer tablet contains: Linagliptin IP 5mg + Dapagliflozin Propanediol Monohydrate eq to Dapagliflozin 10mg + Metformin Hydrochloride (as sustained release form) IP 1000mg for M/s Theon Pharmaceuticals Ltd (Manufacturer) & M/s MSN Laboratories Pvt Ltd. (Marketer) (F. No. 3915) at Rs. 19.64 per tablet excluding GST.

Q

1. The committee deliberated on the matter and recommended retail price on the lines of DPCO amendment vide S.O. No. 2165(E) dated 11.05.2023 as below:

1	Manufacturer Name	M/s Theon Pharmaceuticals Ltd
2	Marketer Name	M/s MSN Laboratories Pvt Ltd. (Applicant)
3	Date of Application	20.03.2024
4	Patented Component I	Linagliptin
5	Patent Holder	M/s Boehringer Ingelheim
6	License Holder	M/s Lupin LTD
7	Date of Patent Expiry	21.02.2022
8	Patented Component II	Dapagliflozin
9	Patent Holder	M/s Astra Zeneca
10	License Holder	M/s Sun Pharma and M/s Abbott Healthcare
11	Date of Patent Expiry	02.10.2020

Calculation of Retail Price

S.N.	Particulars	Data Month	Linagliptin (5mg) + Metformin 1000mg)	Dapagliflozin (10mg) + Metformin 1000mg)
A.	Retail price of FDC excluding Patent & License Holder	August 23	11.52	11.79
B.	Other Component excluding Patent & License Holder	August 23	12.03	11.24
			Dapagliflozin (10mg)	Linagliptin (5mg)
C.	Total		23.55	23.03
D.	Less: 20% of lower of A&B		2.30	2.25
E.	Calculated Price of applied FDC		21.25	20.78
F.	Claimed Price		19.64	19.64
G.	Recommended Price (Lower of worked out and claimed price) per tablet			19.64

(vi) **Agenda Item No. 1(f):** Retail price fixation under Para 5 of DPCO, 2013 – Each film coated bilayer tablet contains: Linagliptin IP 5mg + Dapagliflozin Propanediol Monohydrate eq to Dapagliflozin 10mg + Metformin Hydrochloride (as sustained release form) IP 1000mg for M/s Theon Pharmaceuticals Ltd (Manufacturer) & M/s Lupin Ltd. (Marketer) (F. No. 3932) at Rs. 20.78 per tablet excluding GST.

1. The committee deliberated on the matter and recommended retail price on the lines of DPCO amendment vide S.O. No. 2165(E) dated 11.05.2023 as below:

1	Manufacturer Name	M/s Theon Pharmaceuticals Ltd
2	Marketer Name	M/s Lupin Ltd. (Applicant)
3	Date of Application	27.03.2024
4	Patented Component I	Linagliptin
5	Patent Holder	M/s Boehringer Ingelheim
6	License Holder	M/s Lupin LTD
7	Date of Patent Expiry	21.02.2022
8	Patented Component II	Dapagliflozin
9	Patent Holder	M/s Astra Zeneca
10	License Holder	M/s Sun Pharma and M/s Abbott Healthcare
11	Date of Patent Expiry	02.10.2020

Calculation of Retail Price

S.N.	Particulars	Data Month	Linagliptin (5mg) + Metformin 1000mg)	Dapagliflozin (10mg) + Metformin 1000mg)
A.	Retail price of FDC excluding Patent & License Holder	August 23	11.52	11.79
B.	Other Component excluding Patent & License Holder	August 23	12.03 Dapagliflozin (10mg)	11.24 Linagliptin (5mg)
C.	Total		23.55	23.03
D.	Less: 20% of lower of A&B		2.30	2.25
E.	Calculated Price of applied FDC		21.25	20.78
F.	Claimed Price		31.25	31.25
G.	Recommended Price (Lower of worked out and claimed price) per tablet			20.78

(vii) Agenda Item No. 1(g): Retail price fixation under Para 5 of DPCO, 2013 – Each film coated bilayer tablet contains: Linagliptin IP 5mg + Dapagliflozin Propanediol Monohydrate eq to Dapagliflozin 10mg + Metformin Hydrochloride (as sustained release form) IP 1000mg for M/s Theon Pharmaceuticals Ltd (Manufacturer) & M/s Mankind Pharma Ltd. (Marketer) (F. No. 3938) at Rs. 20.78 per tablet excluding GST.

1. The committee deliberated on the matter and recommended retail price on the lines of DPCO amendment vide S.O. No. 2165(E) dated 11.05.2023 as below:

1	Manufacturer Name	M/s Theon Pharmaceuticals Ltd
2	Marketer Name	M/s Mankind Pharma Ltd. (Applicant)
3	Date of Application	28.03.2024
4	Patented Component I	Linagliptin
5	Patent Holder	M/s Boehringer Ingelheim
6	License Holder	M/s Lupin LTD
7	Date of Patent Expiry	21.02.2022
8	Patented Component II	Dapagliflozin
9	Patent Holder	M/s Astra Zeneca
10	License Holder	M/s Sun Pharma and M/s Abbott Healthcare
11	Date of Patent Expiry	02.10.2020

Calculation of Retail Price

S.N.	Particulars	Data Month	Linagliptin (5mg) + Metformin 1000mg)	Dapagliflozin (10mg) + Metformin 1000mg)
A.	Retail price of FDC excluding Patent & License Holder	August 23	11.52	11.79
B.	Other Component excluding Patent & License Holder	August 23	12.03	11.24
			Dapagliflozin (10mg)	Linagliptin (5mg)
C.	Total		23.55	23.03
D.	Less: 20% of lower of A&B		2.30	2.25
E.	Calculated Price of applied FDC		21.25	20.78
F.	Claimed Price		23.00	23.00
G.	Recommended Price (Lower of worked out and claimed price) per tablet			20.78

(viii) **Agenda Item No. 1(h):** Retail price fixation under Para 5 of DPCO, 2013 - Each film coated bilayer tablet contains: Linagliptin IP 5mg + Dapagliflozin Propanediol Monohydrate eq to Dapagliflozin 10mg + Metformin Hydrochloride (as sustained release form) IP 1000mg for M/s Theon Pharmaceuticals Ltd (Manufacturer) & M/s Intas Pharmaceuticals Ltd. (Marketer) (F. No. 3948) at Rs. 20.78 per tablet excluding GST.

1. The committee deliberated on the matter and recommended retail price on the lines of DPCO amendment vide S.O. No. 2165(E) dated 11.05.2023 as below:

1	Manufacturer Name	M/s Theon Pharmaceuticals Ltd
2	Marketer Name	M/s Intas Pharmaceuticals Ltd. (Applicant)
3	Date of Application	29.03.2024
4	Patented Component I	Linagliptin
5	Patent Holder	M/s Boehringer Ingelheim
6	License Holder	M/s Lupin LTD
7	Date of Patent Expiry	21.02.2022
8	Patented Component II	Dapagliflozin
9	Patent Holder	M/s Astra Zeneca
10	License Holder	M/s Sun Pharma and M/s Abbott Healthcare
11	Date of Patent Expiry	02.10.2020

Calculation of Retail Price

S.N.	Particulars	Data Month	Linagliptin (5mg) + Metformin 1000mg)	Dapagliflozin (10mg) + Metformin 1000mg)
A.	Retail price of FDC excluding Patent & License Holder	August 23	11.52	11.79
B.	Other Component excluding Patent & License Holder	August 23	12.03 Dapagliflozin (10mg)	11.24 Linagliptin (5mg)
C.	Total		23.55	23.03
D.	Less: 20% of lower of A&B		2.30	2.25
E.	Calculated Price of applied FDC		21.25	20.78
F.	Claimed Price		24.00	24.00
G.	Recommended Price (Lower of worked out and claimed price) per tablet			20.78

(ix) **Agenda Item No. 1(i):** Retail price fixation under Para 5 of DPCO, 2013 – Each film coated bilayer tablet contains: Linagliptin IP 5mg + Dapagliflozin Propanediol Monohydrate eq to Dapagliflozin 10mg + Metformin Hydrochloride (as sustained release form) IP 500mg for M/s Theon Pharmaceuticals Ltd (Manufacturer) & M/s Torrent Pharmaceuticals Ltd. (Marketer) (F. No. 3905) at Rs. 18.00 per tablet excluding GST.

1. The committee deliberated on the matter and recommended retail price on the lines of DPCO amendment vide S.O. No. 2165(E) dated 11.05.2023 as below:

R

1	Manufacturer Name	M/s Theon Pharmaceuticals Ltd
2	Marketer Name	M/s Torrent Pharmaceuticals Ltd. (Applicant)
3	Date of Application	14.03.2024
4	Patented Component I	Linagliptin
5	Patent Holder	M/s Boehringer Ingelheim
6	License Holder	M/s Lupin LTD
7	Date of Patent Expiry	21.02.2022
8	Patented Component II	Dapagliflozin
9	Patent Holder	M/s Astra Zeneca
10	License Holder	M/s Sun Pharma and M/s Abbott Healthcare
11	Date of Patent Expiry	02.10.2020

Calculation of Retail Price

S.N.	Particulars	Data Month	Linagliptin (5mg) + Metformin 500mg)	Dapagliflozin (10mg) + Metformin 500mg)
A.	Retail price of FDC excluding Patent & License Holder	August 23	NA	10.50
B.	Other Component excluding Patent & License Holder	August 23	12.03 Dapagliflozin (10mg)	11.24 Linagliptin (5mg)
C.	Total		NA	21.74
D.	Less: 20% of lower of A&B		NA	2.10
E.	Calculated Price of applied FDC		NA	19.64
F.	Claimed Price			18.00
G.	Recommended Price (Lower of worked out and claimed price) per tablet			18.00

(x) **Agenda Item No. 1(j):** Retail price fixation under Para 5 of DPCO, 2013 – Each film coated bilayer tablet contains: Linagliptin IP 5mg + Dapagliflozin Propanediol Monohydrate eq to Dapagliflozin 10mg + Metformin Hydrochloride (as sustained release form) IP 500mg for M/s Theon Pharmaceuticals Ltd (Manufacturer) & M/s Alkem Laboratories Ltd. (Marketer) (F. No. 3907) at Rs. 19.64 per tablet excluding GST.

1. The committee deliberated on the matter and recommended retail price on the lines of DPCO amendment vide S.O. No. 2165(E) dated 11.05.2023 as below:

1	Manufacturer Name	M/s Theon Pharmaceuticals Ltd
2	Marketer Name	M/s Alkem Laboratories Ltd.(Applicant)
3	Date of Application	15.03.2024
4	Patented Component I	Linagliptin
5	Patent Holder	M/s Boehringer Ingelheim
6	License Holder	M/s Lupin LTD
7	Date of Patent Expiry	21.02.2022
8	Patented Component II	Dapagliflozin
9	Patent Holder	M/s Astra Zeneca
10	License Holder	M/s Sun Pharma and M/s Abbott Healthcare
11	Date of Patent Expiry	02.10.2020

Calculation of Retail Price

S.N.	Particulars	Data Month	Linagliptin (5mg) + Metformin 500mg)	Dapagliflozin (10mg) + Metformin 500mg)
A.	Retail price of FDC excluding Patent & License Holder	August 23	NA	10.50
B.	Other Component excluding Patent & License Holder	August 23	12.03 Dapagliflozin (10mg)	11.24 Linagliptin (5mg)
C.	Total		NA	21.74
D.	Less: 20% of lower of A&B		NA	2.10
E.	Calculated Price of applied FDC		NA	19.64
F.	Claimed Price			24.11
G.	Recommended Price (Lower of worked out and claimed price) per tablet			19.64

(xi) Agenda Item No. 1(k): Retail price fixation under Para 5 of DPCO, 2013 – Each film coated bilayer tablet contains: Linagliptin IP 5mg + Dapagliflozin Propanediol Monohydrate eq to Dapagliflozin 10mg + Metformin Hydrochloride (as sustained release form) IP 500mg for M/s Theon Pharmaceuticals Ltd (Manufacturer) & M/s Zydus Healthcare Ltd. (Marketer) (F. No. 3910) at Rs. 19.64 per tablet excluding GST.

1. The committee deliberated on the matter and recommended retail price on the lines of DPCO amendment vide S.O. No. 2165(E) dated 11.05.2023 as below:

1	Manufacturer Name	M/s Theon Pharmaceuticals Ltd
2	Marketer Name	M/s Zydus Healthcare Ltd.(Applicant)
3	Date of Application	15.03.2024
4	Patented Component I	Linagliptin
5	Patent Holder	M/s Boehringer Ingelheim
6	License Holder	M/s Lupin LTD
7	Date of Patent Expiry	21.02.2022
8	Patented Component II	Dapagliflozin
9	Patent Holder	M/s Astra Zeneca
10	License Holder	M/s Sun Pharma and M/s Abbott Healthcare
11	Date of Patent Expiry	02.10.2020

Calculation of Retail Price

S.N.	Particulars	Data Month	Linagliptin (5mg) + Metformin 500mg)	Dapagliflozin (10mg) + Metformin 500mg)
A.	Retail price of FDC excluding Patent & License Holder	August 23	NA	10.50
B.	Other Component excluding Patent & License Holder	August 23	12.03 Dapagliflozin (10mg)	11.24 Linagliptin (5mg)
C.	Total		NA	21.74
D.	Less: 20% of lower of A&B		NA	2.10
E.	Calculated Price of applied FDC		NA	19.64
F.	Claimed Price			50.00
G.	Recommended Price (Lower of worked out and claimed price) per tablet			19.64

(xii) **Agenda Item No. 1(I):** Retail price fixation under Para 5 of DPCO, 2013 – Each film coated bilayer tablet contains: Linagliptin IP 5mg + Dapagliflozin Propanediol Monohydrate eq to Dapagliflozin 10mg + Metformin Hydrochloride (as sustained release form) IP 500mg for M/s Theon Pharmaceuticals Ltd (Manufacturer) & M/s MSN Laboratories Pvt Ltd. (Marketer) (F. No. 3914) at Rs. 18.75 per tablet excluding GST.

1. The committee deliberated on the matter and recommended retail price on the lines of DPCO amendment vide S.O. No. 2165(E) dated 11.05.2023 as below:

1	Manufacturer Name	M/s Theon Pharmaceuticals Ltd
---	--------------------------	-------------------------------

2	Marketer Name	M/s MSN Laboratories Pvt Ltd. (Applicant)
3	Date of Application	20.03.2024
4	Patented Component I	Linagliptin
5	Patent Holder	M/s Boehringer Ingelheim
6	License Holder	M/s Lupin LTD
7	Date of Patent Expiry	21.02.2022
8	Patented Component II	Dapagliflozin
9	Patent Holder	M/s Astra Zeneca
10	License Holder	M/s Sun Pharma and M/s Abbott Healthcare
11	Date of Patent Expiry	02.10.2020

Calculation of Retail Price

S.N.	Particulars	Data Month	Linagliptin (5mg) + Metformin 500mg)	Dapagliflozin (10mg) + Metformin 500mg)
A.	Retail price of FDC excluding Patent & License Holder	August 23	NA	10.50
B.	Other Component excluding Patent & License Holder	August 23	12.03	11.24
			Dapagliflozin (10mg)	Linagliptin (5mg)
C.	Total		NA	21.74
D.	Less: 20% of lower of A&B		NA	2.10
E.	Calculated Price of applied FDC		NA	19.64
F.	Claimed Price			18.75
G.	Recommended Price (Lower of worked out and claimed price) per tablet			18.75

(xiii) **Agenda Item No. 1(m):** Retail price fixation under Para 5 of DPCO, 2013 – Each film coated bilayer tablet contains: Linagliptin IP 5mg + Dapagliflozin Propanediol Monohydrate eq to Dapagliflozin 10mg + Metformin Hydrochloride (as sustained release form) IP 500mg for M/s Theon Pharmaceuticals Ltd (Manufacturer) & M/s Intas Pharmaceuticals Ltd. (Marketer) (F. No. 3925) at Rs. 19.64 per tablet excluding GST.

1. The committee deliberated on the matter and recommended retail price on the lines of DPCO amendment vide S.O. No. 2165(E) dated 11.05.2023 as below:

1	Manufacturer Name	M/s Theon Pharmaceuticals Ltd
2	Marketer Name	M/s Intas Pharmaceuticals Ltd.(Applicant)
3	Date of Application	22.03.2024

Q

4	Patented Component I	Linagliptin
5	Patent Holder	M/s Boehringer Ingelheim
6	License Holder	M/s Lupin LTD
7	Date of Patent Expiry	21.02.2022
8	Patented Component II	Dapagliflozin
9	Patent Holder	M/s Astra Zeneca
10	License Holder	M/s Sun Pharma and M/s Abbott Healthcare
11	Date of Patent Expiry	02.10.2020

Calculation of Retail Price

S.N.	Particulars	Data Month	Linagliptin (5mg) + Metformin 500mg)	Dapagliflozin (10mg) + Metformin 500mg)
A.	Retail price of FDC excluding Patent & License Holder	August 23	NA	10.50
B.	Other Component excluding Patent & License Holder	August 23	12.03 Dapagliflozin (10mg)	11.24 Linagliptin (5mg)
C.	Total		NA	21.74
D.	Less: 20% of lower of A&B		NA	2.10
E.	Calculated Price of applied FDC		NA	19.64
F.	Claimed Price			21.00
G.	Recommended Price (Lower of worked out and claimed price) per tablet			19.64

(xiv) **Agenda Item No. 1(n):** Retail price fixation under Para 5 of DPCO, 2013 – Each film coated bilayer tablet contains: Linagliptin IP 5mg + Dapagliflozin Propanediol Monohydrate eq to Dapagliflozin 10mg + Metformin Hydrochloride (as sustained release form) IP 500mg for M/s Theon Pharmaceuticals Ltd (Manufacturer) & M/s Micro Labs Ltd. (Marketer) (F. No. 3927) at Rs. 15.00 per tablet excluding GST.

1. The committee deliberated on the matter and recommended retail price on the lines of DPCO amendment vide S.O. No. 2165(E) dated 11.05.2023 as below:

1	Manufacturer Name	M/s Theon Pharmaceuticals Ltd
2	Marketer Name	M/s Micro Labs Ltd. (Applicant)
3	Date of Application	23.03.2024
4	Patented Component I	Linagliptin

5	Patent Holder	M/s Boehringer Ingelheim
6	License Holder	M/s Lupin LTD
7	Date of Patent Expiry	21.02.2022
8	Patented Component II	Dapagliflozin
9	Patent Holder	M/s Astra Zeneca
10	License Holder	M/s Sun Pharma and M/s Abbott Healthcare
11	Date of Patent Expiry	02.10.2020

Calculation of Retail Price

S.N.	Particulars	Data Month	Linagliptin (5mg) + Metformin 500mg)	Dapagliflozin (10mg) + Metformin 500mg)
A.	Retail price of FDC excluding Patent & License Holder	August 23	NA	10.50
B.	Other Component excluding Patent & License Holder	August 23	12.03 Dapagliflozin (10mg)	11.24 Linagliptin (5mg)
C.	Total		NA	21.74
D.	Less: 20% of lower of A&B		NA	2.10
E.	Calculated Price of applied FDC		NA	19.64
F.	Claimed Price			15.00
G.	Recommended Price (Lower of worked out and claimed price) per tablet			15.00

(xv) Agenda Item No. 1(o): Retail price fixation under Para 5 of DPCO, 2013 – Each film coated bilayer tablet contains: Linagliptin IP 5mg + Dapagliflozin Propanediol Monohydrate eq to Dapagliflozin 10mg + Metformin Hydrochloride (as sustained release form) IP 500mg for M/s Theon Pharmaceuticals Ltd (Manufacturer) & M/s Mankind Pharma Ltd. (Marketer) (F. No. 3937) at Rs. 19.64 per tablet excluding GST.

1. The committee deliberated on the matter and recommended retail price on the lines of DPCO amendment vide S.O. No. 2165(E) dated 11.05.2023 as below:

1	Manufacturer Name	M/s Theon Pharmaceuticals Ltd
2	Marketer Name	M/s Mankind Pharma Ltd. (Applicant)
3	Date of Application	28.03.2024
4	Patented Component I	Linagliptin
5	Patent Holder	M/s Boehringer Ingelheim

Handwritten signature

6	License Holder	M/s Lupin LTD
7	Date of Patent Expiry	21.02.2022
8	Patented Component II	Dapagliflozin
9	Patent Holder	M/s Astra Zeneca
10	License Holder	M/s Sun Pharma and M/s Abbott Healthcare
11	Date of Patent Expiry	02.10.2020

Calculation of Retail Price

S.N.	Particulars	Data Month	Linagliptin (5mg) + Metformin 500mg)	Dapagliflozin (10mg) + Metformin 500mg)
A.	Retail price of FDC excluding Patent & License Holder	August 23	NA	10.50
B.	Other Component excluding Patent & License Holder	August 23	12.03 Dapagliflozin (10mg)	11.24 Linagliptin (5mg)
C.	Total		NA	21.74
D.	Less: 20% of lower of A&B		NA	2.10
E.	Calculated Price of applied FDC		NA	19.64
F.	Claimed Price			21.00
G.	Recommended Price (Lower of worked out and claimed price) per tablet			19.64

(xvi) **Agenda Item No. 1(p):** Retail price fixation under Para 5 of DPCO, 2013 – Each film coated bilayer tablet contains: Linagliptin IP 5mg + Dapagliflozin Propanediol Monohydrate eq to Dapagliflozin 10mg + Metformin Hydrochloride (as sustained release form) IP 500mg for M/s Theon Pharmaceuticals Ltd (Manufacturer) & M/s Lupin Ltd. (Marketer) (F. No. 3931) at Rs. 19.64 per tablet excluding GST.

1. The committee deliberated on the matter and recommended retail price on the lines of DPCO amendment vide S.O. No. 2165(E) dated 11.05.2023 as below:

1	Manufacturer Name	M/s Theon Pharmaceuticals Ltd
2	Marketer Name	M/s Lupin Ltd. (Applicant)
3	Date of Application	27.03.2024
4	Patented Component I	Linagliptin
5	Patent Holder	M/s Boehringer Ingelheim
6	License Holder	M/s Lupin LTD

7	Date of Patent Expiry	21.02.2022
8	Patented Component II	Dapagliflozin
9	Patent Holder	M/s Astra Zeneca
10	License Holder	M/s Sun Pharma and M/s Abbott Healthcare
11	Date of Patent Expiry	02.10.2020

Calculation of Retail Price

S.N.	Particulars	Data Month	Linagliptin (5mg) + Metformin 500mg)	Dapagliflozin (10mg) + Metformin 500mg)
A.	Retail price of FDC excluding Patent & License Holder	August 23	NA	10.50
B.	Other Component excluding Patent & License Holder	August 23	12.03 Dapagliflozin (10mg)	11.24 Linagliptin (5mg)
C.	Total		NA	21.74
D.	Less: 20% of lower of A&B		NA	2.10
E.	Calculated Price of applied FDC		NA	19.64
F.	Claimed Price			26.79
G.	Recommended Price (Lower of worked out and claimed price) per tablet			19.64

Agenda Item No. 2 (a): Retail price fixation under Para 5 of DPCO, 2013 – Each film coated tablet contains: Glimepiride IP 2mg + Sitagliptin Phosphate Monohydrate eq to Sitagliptin 100mg for M/s Exemed Pharmaceuticals (Manufacturer) & M/s Mankind Pharma Ltd (Marketer) (F. No. 3950) at Rs. 15.38 per tablet excluding GST.

1. The committee deliberated on the matter and recommended retail price on the lines of DPCO amendment vide S.O. No. 2165(E) dated 11.05.2023 as below:

1	Manufacturer Name	M/s Exemed Pharmaceuticals
2	Marketer Name	M/s Mankind Pharma Limited (Applicant)
3	Date of Application	26.03.2024
4	Patented Component I	Sitagliptin
5	Patent Holder	M/s MSD Pharmaceuticals Private Ltd
6	License Holder	M/s Sun Pharma
7	Date of Patent Expiry	05.07.2022

fr

Calculation of Retail Price

S.N.	Particulars	Data Month for PTR	Rs.
A.	Retail price of Sitagliptin (100mg) excluding Patent & License Holder	Aug 23	10.74
B.	Ceiling Price of Glimepiride 2mg (S.O. 1574(E) dated 31.03.2023 & 4663(E) dated 25.10.2023)	Aug 23	5.80
C.	Total		16.54
D.	Less: 20% of lower of A&B		1.16
E.	Calculated Price of applied FDC		15.38
F.	Claimed Price		22.00
G.	Recommended Price (Lower of worked out and claimed price) per tablet		15.38

Agenda Item No. 2 (b): Retail price fixation under Para 5 of DPCO, 2013 – Each film coated tablet contains: Glimepiride IP 2mg + Sitagliptin Phosphate Monohydrate eq to Sitagliptin 100mg for M/s Exemed Pharmaceuticals (Manufacturer) & M/s Eris Lifesciences Ltd (Marketer) (F. No. 3930) at Rs. 15.38 per tablet excluding GST.

1. The committee deliberated on the matter and recommended retail price on the lines of DPCO amendment vide S.O. No. 2165(E) dated 11.05.2023 as below:

1	Manufacturer Name	M/s Exemed Pharmaceuticals
2	Marketer Name	M/s Eris Lifesciences Ltd. (Applicant)
3	Date of Application	26.03.2024
4	Patented Component I	Sitagliptin
5	Patent Holder	M/s MSD Pharmaceuticals Private Ltd
6	License Holder	M/s Sun Pharma
7	Date of Patent Expiry	05.07.2022

Calculation of Retail Price

S.N.	Particulars	Data Month for PTR	Rs.
A.	Retail price of Sitagliptin (100mg) excluding Patent & License Holder	Aug 23	10.74
B.	Ceiling Price of Glimepiride 1mg (S.O. 1574(E) dated 31.03.2023 & 4663(E) dated 25.10.2023)	Aug 23	5.80
C.	Total		16.54



D.	Less: 20% of lower of A&B		1.16
E.	Calculated Price of applied FDC		15.38
F.	Claimed Price		31.25
G.	Recommended Price (Lower of worked out and claimed price) per tablet		15.38

Agenda Item No. 2 (c): Retail price fixation under Para 5 of DPCO, 2013 – Each film coated tablet contains: Glimepiride IP 1mg + Sitagliptin Phosphate Monohydrate eq to Sitagliptin 100mg for M/s Exemed Pharmaceuticals (Manufacturer) & M/s Mankind Pharma Ltd (Marketer) (F. No. 3949) at Rs. 13.70 per tablet excluding GST.

1. The committee deliberated on the matter and recommended retail price on the lines of DPCO amendment vide S.O. No. 2165(E) dated 11.05.2023 as below:

1	Manufacturer Name	M/s Exemed Pharmaceuticals
2	Marketer Name	M/s M/s Mankind Pharma Ltd (Applicant)
3	Date of Application	31.03.2024
4	Patented Component I	Sitagliptin
5	Patent Holder	M/s MSD Pharmaceuticals Private Ltd
6	License Holder	M/s Sun Pharma
7	Date of Patent Expiry	05.07.2022

Calculation of Retail Price

S.N.	Particulars	Data Month for PTR	Rs.
A.	Retail price of Sitagliptin (100mg) excluding Patent & License Holder	Aug 23	10.74
B.	Ceiling price of Glimepiride 1mg tablet (S.O. no 1574 (E) dated 31.03.2023)	Aug 23	3.70
C.	Total		14.44
D.	Less: 20% of lower of A&B		0.74
E.	Calculated Price of applied FDC		13.70
F.	Claimed Price		20.00
G.	Recommended Price (Lower of worked out and claimed price) per tablet		13.70

Agenda Item No. 2 (d): Retail price fixation under Para 5 of DPCO, 2013 – Each film coated tablet contains: Glimepiride IP 1mg + Sitagliptin Phosphate Monohydrate eq to Sitagliptin 100mg for M/s Exemed Pharmaceuticals (Manufacturer) & M/s Eris Lifesciences Ltd (Marketer) (F. No. 3929) at Rs. 13.70 per tablet excluding GST.

1. The committee deliberated on the matter and recommended retail price on the lines of DPCO amendment vide S.O. No. 2165(E) dated 11.05.2023 as below:

1	Manufacturer Name	M/s Exemed Pharmaceuticals
2	Marketer Name	M/s Eris Lifesciences Ltd. (Applicant)
3	Date of Application	26.03.2024
4	Patented Component I	Sitagliptin
5	Patent Holder	M/s MSD Pharmaceuticals Private Ltd
6	License Holder	M/s Sun Pharma
7	Date of Patent Expiry	05.07.2022

Calculation of Retail Price

S.N.	Particulars	Data Month for PTR	Rs.
A.	Retail price of Sitagliptin (100mg) excluding Patent & License Holder	Aug 23	10.74
B.	Ceiling Price of Glimepiride 1mg (S.O. 1574(E) dated 31.03.2023)	Aug 23	3.70
C.	Total		14.44
D.	Less: 20% of lower of A&B		0.74
E.	Calculated Price of applied FDC		13.70
F.	Claimed Price		26.79
G.	Recommended Price (Lower of worked out and claimed price) per tablet		13.70

Agenda Item No. 3: Approval for ceiling price of different dosage forms and strength of I.V Fluids with packaging in non-glass with special features dated 24.04.2023 being filed by M/s Aculife Healthcare Pvt. Ltd.

3.1 The Committee noted that M/s Aculife Healthcare Pvt. Ltd requested to extend the ceiling prices of the formulations with packaging in Non-Glass container in plastic bottle with EUROHEAD having special features on 24.04.2023 & complete documents were submitted on 07.11.2023. The company has claimed for the following products having special feature like (a) Aseptic Blow Fill Seal (ABFS) process (b) Low Density Polyethylene Plastic (c) self- sealability (d) self collapsibility and (e) Precise Pressure Dosing System:

Sl.No	Medicines	Dosage form and strength	Packsize
1	Dextrose (Glucose)	Injection (25% w/v)	100 ml / 500ml With special feature with euro head
2	Mannitol	Injection 20%	100 ml / 350ml pack

			With special feature with euro head
3	Metronidazole	Injection (0.5% w/v)/500mg/100ml	100ml With special feature with euro head
4.	Ciprofloxacin	Injection 200mg/100mL	100ml With special feature with euro head

3.2 The matter was earlier deliberated in 52nd, 53rd, 55th, 56th & 57th meeting of MDC held on 11.07.2023, 08.08.2023, 17.10.2023, 20.12.2023 & 27.02.2024 respectively. The representative of the company was asked to join the 53rd, 55th & 56th meeting. However, the company did not join the 53rd meeting & 56th meeting. The representatives of the company joined the 55th meeting of MDC through Video Conferencing and demonstrated their product to the committee w.r.t. special features claimed. The representatives of the company also joined the 57th meeting of MDC to clarify the contradictory statements given w.r.t. plastic granules LDPE of Pharma/Medical grade.

3.3 The Committee in its 57th meeting deliberated upon the matter & directed to submit the following:

- Test report of three consecutive batches for plastic granules used as per IP standards
- Report on Residual quantity after administration in respect of the IV fluids applied

3.4 The applicant vide letter dated 27.02.2024 submitted their response on the above query of the MDC. The Committee noted that the ceiling price for Dextrose (Glucose Injection 25% w/v) and Mannitol Injection 20% has been notified on per ML basis and a separate ceiling price for these formulation in special feature have been notified on per ml basis for the pack size of 100ml only. However, the company has applied for separate ceiling price for 500ml pack for Dextrose (Glucose Injection 25% w/v) and 350ml pack for Mannitol Injection 20% in addition to 100ml pack. The Committee further noted that the applicant has provided a copy of the license for the same.

3.5 The Committee deliberated in detail on the submission of the company w.r.t. special features claimed & recommended to extend the present applicable ceiling price of the applied formulations having special features for the packsizes as given below to M/s Aculife Healthcare Pvt. Ltd:

Sl.No	Medicines	Dosage form and strength	Unit	Ceiling price (wef 01.04.2024 with WPI @0.00551%)
1	Dextrose (Glucose)	Injection (25% w/v)	100 ml/500ml With special feature with euro head	0.24 per ml
2	Mannitol	Injection 20%	100 ml / 350ml pack With special feature with euro head	0.40 per ml

3	Metronidazole	Injection (0.5% w/v)/ 500mg/100 ml	100ml With special feature with euro head	0.25 per ml
4.	Ciprofloxacin	Injection 200mg/100ml	100ml With special feature with euro head	0.23 per ML (0.20 per ML + 15% on account of special packaging) (Note 1)

Note 1: The Committee noted that separate ceiling price for special feature packaging of this product has not yet been fixed for any company. The price for normal packaging is Rs. 0.20 per ml. However, committee recommended the separate ceiling price at Rs. 0.23 per ml (0.20 per ML + 15% on account of special packaging) in line with other formulations.

Agenda Item No. 4: Application for extension of ceiling price of I.V Fluids with packaging in non-glass with special feature by M/s Puniska Injectables Private Limited in line with relevant pricing notification under para 11(3) of DPCO,2013.

4.1 The Committee noted that M/s Puniska Injectables Private Limited requested to extend the ceiling prices of the formulations with packaging in non-glass with special feature in line with relevant pricing notification under para 11(3) of DPCO,2013 on 27.05.2023 & complete documents were submitted on 07.12.2023. The company has claimed for the following products having special feature like "(i) self-collapsibility and self- sealability (ii) not having air-vent and (iii) there is no chance of contamination during manufacture/ infusion/ admixing levels:

Product Name	Pack Size
Sodium Chloride 0.9%	1000 ML, 500 ML, 250ML & 100 ML
Glucose 5% + Sodium chloride 0.9% (DNS)	1000 ML & 500 ML
Glucose Injection 5% (5D)	1000 ML & 500 ML
Ringer Lactate	500 ML & 250 ML
Metronidazole Injection 0.5% w/v	100 ML

4.2 The matter was earlier deliberated in 56th & 57th meeting of MDC held on 20.12.2023 & 27.02.2024 respectively. The representatives of the company joined the 57th meeting of MDC through Video Conferencing and demonstrated their product to the committee w.r.t. special features claimed. The Committee deliberated up on the matter in detail and directed as follows:

- Applicant has submitted the flow rate data of one bottle of each pack of 100ml, 250ml, 500ml & 1000 ml of Sodium Chloride Injection 0.9%. Applicant may be directed to submit the detailed flow rate analysis of more than one bottle of each pack size along with standard deviation, if any, in data
- Test report of three consecutive batches for plastic granules used as per IP standards

4.3 The applicant vide letter dated 12.03.2024 submitted their response on the above query of the MDC. The Committee deliberated in detail on the submission of the company w.r.t. special features claimed & recommended to extend the present applicable ceiling

price of the applied formulations having special features as given below to M/s Puniska Injectables Private Limited:

Sl. No	Medicines	Dosage form and strength	Unit	Ceiling price (wef 01.04.2024 with WPI @0.00551%)
1	Glucose	Injection 5%	1000ml non-Glass with special features	95.11
2	Glucose	Injection 5%	500ml non-Glass with special features	82.27
3	Glucose (A) + Sodium Chloride (B)	Injection 5% (A) + 0.9% (B)	1000ml non-Glass with special features	99.94
4	Glucose (A) + Sodium Chloride (B)	Injection 5% (A) + 0.9% (B)	500ml non-Glass with special features	85.52
5	Sodium Chloride	Injection 0.9%	100ml non-Glass with special features	42.06
6	Sodium Chloride	Injection 0.9%	250ml non-Glass with special features	62.10
7	Sodium Chloride	Injection 0.9%	500ml non-Glass with special features	87.94
8	Sodium Chloride	Injection 0.9%	1000ml non-Glass with special features	98.51
9	Ringer lactate	Injection 500 ml	Each 500 ml pack having special features	64.96
10	Ringer lactate	Injection 250 ml	Each 250 ml pack having special features	50.99
11	Metronidazole	Injection (0.5%w/v) /500mg/100ml in 100ml pack for packages in non-glass container in plastic bottle with euro head having special features	Per ml	0.25

Agenda Item No. 5: Application to fix a separate Ceiling Price under Paragraph 11(3) of DPCO-2013, of a Scheduled formulation of Amoxicillin 200 mg + Clavulanic acid 28.5 mg Suspension in a Dual Chamber Pack with Novel Technology, being introduced in India for the first time. -Seeking additional Price for Dual Chamber Pack over and above Existing Ceiling Price.

5.1 The Committee noted that the matter relates to application filed by M/s Sun Pharmaceuticals Industries Limited on 29.09.2023 for fixation of separate ceiling price

for scheduled formulation of Amoxicillin 200 mg + Clavulanic acid 28.5 mg Suspension in a Dual Chamber Pack with Novel Technology under para 11(3) of DPCO, 2013.

5.2 The matter was earlier deliberated in 56th & 57th meeting of MDC held on 15.12.2023 & 27.02.2024 respectively. The representatives of the company gave detailed presentation before the Committee in its 57th meeting held on 27.02.2024 and also attended the 59th meeting. The committee recalled the deliberations in the matter as held in earlier meetings that the applicant was asked to submit following documents in 57th meeting:

- i. Published literature / clinical study / evidence that the dual chamber pack helps in reducing the clinical error or improved compliance as claimed.
- ii. As informed by the company, the new package will be sold with Purified water IP. Therefore, regulatory approval of the drug mentioning about the purified water IP is required along with the label claim of the same.

5.3 The Committee noted that the applicant vide letter dated 03.04.2024 has submitted their response on the above query of the MDC. The applicant informed that this kind of Novel Pack is not available anywhere in the world, therefore no published literature on this novel pack is available nationally or internationally. The Committee noted that the applicant has submitted a self-commissioned survey report dated 28.06.2023 and not Published literature / clinical study / evidence in support of their claim. The applicant has submitted license dated 19.01.2021 from SLA.

5.4 Committee noted that said survey report mentions that reconstitution time and spillage are the major challenges while administering the formulation in conventional packing which can be overcome by their new packing. Also, the survey reports, inter-alia, concludes that novel technology dual chamber PFOS pack will help in better efficacy (therapeutic advantage) because of accurate reconstitution and maintain hygiene while reconstitution and administration of the product. However, in the survey report there is no data / evidence that shows reduction in reconstitution time and spillage and also does not provide any evidence/supporting documents for their claim of improved efficacy of the product due to innovative packaging better efficacy (therapeutic advantage).

5.5 Therefore, in view of the above deliberations, the Committee did not find the case fit for separate ceiling price under Para 11(3). Hence, the Committee recommended to reject the application.

Agenda Item No. 6: Application received for special Retail price of "Flagyl Gel with Soft Tip Applicator" under Para 11(3) of DPCO 2013 for incremental innovation.

6.1 The Committee noted that the matter relates to application filed by M/s Abbott Healthcare Pvt. Ltd. on 25.10.2023 claiming the special retail price on account of Incremental Innovation of "Flagyl Gel with Soft Tip Applicator under para 11(3) of DPCO, 2013.

6.2 The matter was earlier deliberated in 56th & 57th meeting of MDC held on 15.12.2023 & 27.02.2024 respectively. The representatives of the company gave detailed presentation before the Committee in its 57th meeting held on 27.02.2024. The committee recalled the deliberations in the matter as held in earlier meetings that the applicant was asked to submit following documents in 57th meeting:

- i. Published literature/ clinical study/ evidence that the applicator helps in administering the drug to improve the compliance of patients, compared to the same drug without the applicator.
- ii. If the evidence for the benefit of the applicator is only in a subset of patients, the company may provide this detail.
- iii. Comments regarding whether the applicator would be classified as a medical device
- iv. The quantum of the residual drug in the applicator.
- v. Why this applicator needs to be sold with the drug itself? It is more like additional/optional package item that can be sold separately.
- vi. Data with respect to bacterial load on multiple usage duly supported with clinical data.

6.3 The committee noted that the applicant vide letter dated 02.04.2024 submitted their response on the above queries of the MDC. The Committee deliberated in detail on the submission of the company & observed that:

- i. The applicant had submitted Patent application filed for European & US Patent but has not submitted Published literature/ clinical study/ evidence that the applicator helps in administering the drug to improve the compliance of patients, compared to the same drug without the applicator.
- ii. Report titled "A Day on the Field with our Sales force (Oro Care)" submitted by the applicant in support of benefit of the applicator in a subset of patients is not satisfactory.

- iii. The applicant in its reply stated that the applicator is designed to create a “drug-device combination” for application of said medicinal product and the tube where applicator must be fixed before application. It observed that as per NDCT rules 2019, a drug-device combination is a new drug for which a separate license is required. However, the applicant has not submitted the same.
- iv. The applicant has stated that the device cannot be separately sold to avoid mishandled, misunderstood, or misused for other product /application which might result in non-desired therapeutic effects. The Committee opined that the concerns highlighted by the company may occur even when the applicator is sold with the formulation for which separate price is sought.

6.4 The Committee in view of above deliberations decided that the justifications provided by the company are not satisfactory for differential price. Hence, the Committee recommended to reject the application.

Agenda Item No. 7: Application filed by M/s Cipla Limited vide their letter dated 15.02.2024 for grant of separate price/special price for 'Ciphaler inhaler device' under the provision of Para 11(3) of DPCO, 2013.

7.1 The Committee noted that M/s Cipla limited had earlier applied for grant of special price for the same product vide letter dated 28.05.2021. The matter was earlier deliberated in 33rd, 34th & 35th meeting of MDC held on 21.06.2021, 26.07.2021 & 18.08.2021 respectively. The Committee in its 35th meeting observed that the claim of M/s Cipla Ltd regarding the efficacy of the product was yet to be validated and the report as submitted by M/s Cipla Ltd was not based on the product of M/s Cipla Ltd. Accordingly, the committee decided to reject the application of M/s Cipla Ltd for grant of separate price / special price for 'Ciphaler Inhaler Device' under the provisions of Para 11(3) of DPCO, 2013. Further, the matter was placed in 92nd Authority meeting held on 08.09.2021, wherein the Authority accepted the recommendation of the MDC and rejected the application.

7.2 M/s Cipla Limited has now submitted fresh application on 15.02.2024 along with the clinical study report of the Ciphaler device & requested for separate ceiling price on account of incremental innovation.

7.3 The Committee deliberated upon the matter in detail and decided that the applicant may be called in next meeting of MDC to explain the innovation as claimed.

The meeting ended with a vote of thanks to all.

Rashmi
20/5/24
(Rashmi Tahiliani)
Director (Pricing)

Copy to:
All members of the Committee.

Composition; Unagliptin IP 5mg + Metformin 1000mg

Number of Companies consisting of Market Share of 1% & Above						
Sum of MAT value considered for price calculation (In Lakhs)						0.00
Sum of PTR per unit considered for price calculation						9.93
Number of Packs considered						1
Average PTR						9.93
Add : 16% Retailer Margin						1.59
Retail Price (without local taxes)						11.52
% Reduction with compared to Highest Price						0.00%

Minimum Price (Rs.)			9.93
Maximum Price (Rs.)			9.93
Average of all considered (Rs.)			9.93
Retail Price (Rs.)			11.52

[illegible]

Note: In view of DPCO Amendment Vide S.O. No. 2165(E) dated 11.05.2023, Patent Holder of Linagliptin i.e. M/s Boehringer Ingelheim & License holder i.e. M/s Lupin Ltd, Is not considered for price fixation.

Dapagliflozin 10mg + Metformin 1000mg

Number of Companies consisting of Market Share of 1% & Above					16
Sum of MAT value considered for price calculation (in Lakhs)					5,248.95
Sum of PTR per unit considered for price calculation					233.65
Number of Packs considered					23
Average PTR					10.16
Add : 16% Retailer Margin					1.63
Retail Price (without local taxes)					11.79
% Reduction with compared to Highest Price					31.95%

Minimum Price (Rs.)			5.48
Maximum Price (Rs.)			14.93
Average of all considered (Rs.)			10.16
Retail Price (Rs.)			11.79

S.No.	Pack Description	छाप BRAND	कंपनी Company	Strength	Pack Size	Unit	TOTAL MAT PTR (Rs.)	56,09,90,905 MAT(Rs.)	100% SKU wise MAT %	Brandwise MAT (Ignoring 0% MAT)	Qualify (Y/N) Y=Yes N=No	M3 Price per Unit (Rs.)	Price per Unit (Rs.) Considered
1	GLEDEPA MEY 10/1000 MG TABLET XR 7	GLEDEPA MEY	ABBOTT HEALTHCARE PVT. LTD	10/1000 MG	7	TABLET XR	312.14						
2	GLUIECT M 10/1000 MG TABLET 15	GLUIECT M	ABBOTT HEALTHCARE PVT. LTD	10/1000 MG	15	TABLET	129.11						
3	GLUIECT TRIO 10/1000 MG TABLET 10	GLUIECT TRIO	ABBOTT HEALTHCARE PVT. LTD	10/1000 MG	10	TABLET	164.24						
4	DAXIGA M 10/1000 MG TABLET 10	DAXIGA M	ACMEDIX PHARMA LLP	10/1000 MG	10	TABLET	56.43	37864.53	0.01%	0.01%	N	5.64	
5	DAPALEX M 10/1000 MG TABLET 10	DAPALEX M	AJANTA PHARMA LTD	10/1000 MG	10	TABLET	117.86	711402.96	0.13%	0.13%	N	11.78	
6	SWITDAPA M 10/1000 MG TABLET XR 10	SWITDAPA M	AKUMENTIS HEALTHCARE LTD	10/1000 MG	10	TABLET XR	85	2257260.00	0.40%	0.40%	N	8.50	
7	VOAGE M 10/1000 MG TABLET 10	VOAGE M	ALEMBIC LTD	10/1000 MG	10	TABLET	93.07	14221560.40	2.54%	2.54%	Y	9.31	9.31
8	DAPANORM M FORTE 10/1000 MG TABLET 10	DAPANORM M	ALKEM LABORATORIES LTD.	10/1000 MG	10	TABLET	113.57	53769782.53	9.58%	9.58%	Y	11.36	11.36
9	DAPAZOL M 10/1000 MG TABLET 10	DAPAZOL M	ALTEUS BIOGENICS PVT.LTD.	10/1000 MG	10	TABLET	126.36	121871.36	0.02%	0.02%	N	12.64	
10	CIDIDAP M 10/1000 MG TABLET 10	CIDIDAP M	APEX LABORATORIES LTD.	10/1000 MG	10	TABLET	85	1454520.00	0.26%	0.26%	N	8.50	
11	DAPRICA M FORTE 10/1000 MG TABLET 10	DAPRICA M	APRICA HEALTHCARE PVT LTD	10/1000 MG	10	TABLET	105.69	2901794.04	0.52%	0.52%	N	10.57	
12	GLUFLOZIN MF FORTE 10/1000 MG TABLET 15	GLUFLOZIN MF	ARISTO PHARMACEUTICALS PVT.LTD	10/1000 MG	15	TABLET	133.57	5355889.86	0.95%	0.95%	N	8.90	
13	XIGDUO 10/1000 MG TABLET XR 7	XIGDUO	ASTRAZENECA PHARMA INDIA LTD	10/1000 MG	7	TABLET XR	360.72						
14	DIABIZ M FORTE 10/1000 MG TABLET 15	DIABIZ M	BLUE CROSS LABORATORIES LTD	10/1000 MG	15	TABLET	107.14	707231.14	0.13%	0.13%	N	7.14	
15	DAPASACH M 10/1000 MG TABLET 10	DAPASACH M	CIPLA LTD.	10/1000 MG	10	TABLET	85.51	1724907.72	0.31%	0.31%	N	8.55	
16	DAPABITE M 10/1000 MG TABLET 10	DAPABITE M	CORONA	10/1000 MG	10	TABLET	107.86	13881958.98	2.47%	2.47%	Y	10.79	10.79
17	DAPLO MF 10/1000 MG TABLET 10	DAPLO MF	DR. REDDYS LABORATORIES LTD	10/1000 MG	10	TABLET	149.29	11394857.83	2.03%	2.03%	Y	14.93	14.93
18	DAPAGZA M 10/1000 MG TABLET 10	DAPAGZA M	EMCURE PHARMACEUTICALS LTD	10/1000 MG	10	TABLET	85.57	1458455.08	0.26%	0.26%	N	8.56	
19	EMILDAP M 10/1000 MG TABLET 10	EMILDAP M	EMCURE PHARMACEUTICALS LTD	10/1000 MG	10	TABLET	85.57	2089790.54	0.37%	0.37%	N	8.56	
20	GLUXIT M FORTE 10/1000 MG TABLET 10	GLUXIT M	ERIS LIFESCIENCES LTD	10/1000 MG	10	TABLET	114.31	22745839.75	4.05%	4.05%	Y	11.43	11.43
21	DAPA GOLD M 10/1000 MG TABLET 15	DAPA GOLD M	HBC LIFESCIENCES PVT LTD	10/1000 MG	15	TABLET	105	6521014.35	1.16%	1.16%	Y	7.00	7.00
22	DIMPRIDE M FORTE 10/1000 MG TABLET 10	DIMPRIDE M	INDOCHEMIE HEALTH SPECIALITIES PVT. LTD.	10/1000 MG	10	TABLET	94.48	392564.40	0.07%	0.07%	N	9.45	
23	DAPARYL M 10/1000 MG TABLET 10	DAPARYL M	INTAS PHARMACEUTICALS LTD	10/1000 MG	10	TABLET	113.57	33755834.51	6.02%	6.02%	Y	11.36	11.36
24	DAPAVEL M 10/1000 MG TABLET 10	DAPAVEL M	INTAS PHARMACEUTICALS LTD	10/1000 MG	10	TABLET	113.57	34676957.94	6.18%	6.18%	Y	11.36	11.36
25	T2C M 10/1000 MG TABLET 15	T2C M	IPCA LABORATORIES PVT LTD.	10/1000 MG	15	TABLET	134.04	1808601.72	0.32%	0.32%	N	8.94	
26	DAPABLESS MF 10/1000 MG TABLET 10	DAPABLESS MF	JAGSONPAL PHARMACEUTICALS LTD	10/1000 MG	10	TABLET	82	16482.00	0.00%	0.00%	N	8.20	
27	DAPACOSE M FORTE 10/1000 MG TABLET 10	DAPACOSE M	JB CHEMICALS	10/1000 MG	10	TABLET	99.4	5784447.80	1.03%	1.03%	Y	8.94	8.94
28	DAPAEASE M FORTE 10/1000 MG TABLET 10	DAPAEASE M	JUBILANT GENERICS LIMITED	10/1000 MG	10	TABLET	77.14	327769.96	0.06%	0.06%	N	7.71	
29	DAGUPACK M 10/1000 MG TABLET 10	DAGUPACK M	KOYE PHARMACEUTICALS PVT. LTD.	10/1000 MG	10	TABLET	99.29	754746.89	0.13%	0.13%	N	9.93	
30	DAPAHENZ M 10/1000 MG TABLET 10	DAPAHENZ M	LA RENON	10/1000 MG	10	TABLET	120.71	1569109.29	0.28%	0.28%	N	12.07	
31	SUGAFLO M FORTE 10/1000 MG TABLET 15	SUGAFLO M	LLOYD HEALTHCARE PVT.LTD	10/1000 MG	15	TABLET	161.44	654484.34	0.12%	0.12%	N	10.76	
32	DAPATURN M FORTE 10/1000 MG TABLET 10	DAPATURN M	LUPIN LTD	10/1000 MG	10	TABLET	98.21	8448349.24	1.51%	1.51%	Y	9.82	9.82

33	DAMITA M 10/1000 MG TABLET 10	DAMITA M	MACLEODS PHARMACEUTICALS PVT.LTD	10/1000 MG	10	TABLET	67.12	1261959.58	0.22%	1.77%	Y	8.71	6.71
34	DAMITA M 10/1000 MG TABLET 15	DAMITA M	MACLEODS PHARMACEUTICALS PVT.LTD	10/1000 MG	15	TABLET	129.11	8693496.62	1.55%	1.77%	Y	8.61	8.81
35	DAPAMAC M 10/1000 MG TABLET 10	DAPAMAC M	MACLEODS PHARMACEUTICALS PVT.LTD	10/1000 MG	10	TABLET	64.76	2054522.29	0.37%	3.39%	Y	6.48	6.48
36	DAPAMAC M 10/1000 MG TABLET 15	DAPAMAC M	MACLEODS PHARMACEUTICALS PVT.LTD	10/1000 MG	15	TABLET	129.11	16925505.19	3.02%	3.39%	Y	8.61	8.61
37	JUSTOZA M 10/1000 MG TABLET 10	JUSTOZA M	MANKIND PHARMACEUTICALS LTD.	10/1000 MG	10	TABLET	90.4	24827456.00	4.43%	6.73%	Y	9.04	9.04
38	JUSTOZA M 10/1000 MG TABLET 15	JUSTOZA M	MANKIND PHARMACEUTICALS LTD.	10/1000 MG	15	TABLET	135.6	12882135.60	2.30%	6.73%	Y	9.04	9.04
39	SGLTD M 10/1000 MG TABLET 10	SGLTD M	MANKIND PHARMACEUTICALS LTD.	10/1000 MG	10	TABLET	90.4	11298824.80	2.01%	2.01%	Y	9.04	9.04
40	DAPABUS M 10/1000 MG TABLET 10	DAPABUS M	MED MANOR ORGANICS PVT LTD.	10/1000 MG	10	TABLET	97.86	11547.48	0.00%	0.00%	N	9.79	
41	DAPANOVA M 10/1000 MG TABLET 15	DAPANOVA M	MEDLEY PHARMACEUTICALS	10/1000 MG	15	TABLET	182.14	17978857.26	3.20%	3.20%	Y	12.14	12.14
42	ZUCAPRIDE M 10/1000 MG TABLET 10	ZUCAPRIDE M	MICRO LABS LTD	10/1000 MG	10	TABLET	115.71	59408406.75	10.59%	10.59%	Y	11.57	11.57
43	DAJIO M 10/1000 MG TABLET 10	DAJIO M	MICRO LABS LTD	10/1000 MG	10	TABLET	115	10921355.92	1.95%	1.95%	Y	11.50	11.50
44	DAPAONE M 10/1000 MG TABLET 10	DAPAONE M	MSN LABORATORIES LTD	10/1000 MG	10	TABLET	105.86	4350155.45	0.78%	0.78%	N	10.59	
45	DAPABEST M 10/1000 MG TABLET 10	DAPABEST M	PANACEA BIOTEC LTD	10/1000 MG	10	TABLET	88.56	116013.60	0.02%	0.02%	N	8.86	
46	GLIFOPRIME M 10/1000 MG TABLET 15	GLIFOPRIME M	PRIMUS REMEDIES PVT LTD	10/1000 MG	15	TABLET	134.04	459087.00	0.08%	0.08%	N	8.84	
47	DPO M 10/1000 MG TABLET 10	DPO M	RPG LIFE SCIENCES LTD.	10/1000 MG	10	TABLET	92.85	673112.38	0.12%	0.12%	N	9.29	
48	SINKIGA M FORTE 10/1000 MG TABLET 10	SINKIGA M	SINSAN PHARMACEUTICALS	10/1000 MG	10	TABLET	133.93	152948.06	0.03%	0.03%	N	13.39	
49	MDAPA 10 M FORTE 10/1000 MG TABLET 10	MDAPA 10 M FORTE	SINSAN PHARMACEUTICALS	10/1000 MG	10	TABLET	133.93	7767.94	0.00%	0.00%	N	13.39	
50	OXRAMET 10/1000 MG TABLET XR 7	OXRAMET	SUN PHARMA LABORATORIES LTD.	10/1000 MG	7	TABLET XR	79.5						
51	DAPEFY M 10/1000 MG TABLET XR 7	DAPEFY M	SUN PHARMA LABORATORIES LTD.	10/1000 MG	7	TABLET XR	79.5						
52	GLUCRETA M 10/1000 MG TABLET 10	GLUCRETA M	TORRENT PHARMACEUTICALS LTD.	10/1000 MG	10	TABLET	117.96	58032090.88	10.34%	10.34%	Y	11.80	11.80
53	DGSON M 10/1000 MG TABLET 10	DGSON M	UNISON PHARMACEUTICALS	10/1000 MG	10	TABLET	58.71	1424696.34	0.25%	0.25%	N	5.87	
54	UDAPA M 10/1000 MG TABLET XR 10	UDAPA M	USV PVT LTD	10/1000 MG	10	TABLET XR	114.22	64203933.16	11.44%	11.44%	Y	11.42	11.42
55	ZINODAP M 10/1000 MG TABLET SR 15	ZINODAP M	WOCKHARDT LTD	10/1000 MG	15	TABLET SR	119.76	3460574.04	0.62%	0.62%	N	7.98	
56	DIUTEN M 10/1000 MG TABLET 15	DIUTEN M	WOCKHARDT LTD	10/1000 MG	15	TABLET	138.36	13005.84	0.00%	0.00%	N	9.22	
57	DAPASET M FORTE 10/1000 MG TABLET 10	DAPASET M	WONSET HEALTH CARE PRIVATE LIMITED	10/1000 MG	10	TABLET	87.14	3058.18	0.00%	0.00%	N	8.71	
58	DAPAFORMIN 10/1000 MG TABLET 10	DAPAFORMIN	ZUVENTUS HEALTHCARE LTD	10/1000 MG	10	TABLET	96.43	1079340.99	0.19%	0.19%	N	9.64	
59	DAPAGLYN M 10/1000 MG TABLET 15	DAPAGLYN M	ZYDUS CADILA - ZHL	10/1000 MG	15	TABLET	155.86	31195704.57	5.56%	5.56%	Y	10.39	10.39
		Rs. Per tablet											
	Worked out Retail Price	11.79	Excluding GST										

Note: In view of DPCO Amendment Vide S.O. No. 2165(E) dated 11.05.2023, Patent Holder of Dapagliflozin i.e. M/s Astra Zeneca & License holder i.e. M/s Sun Pharma and M/s Abbott Healthcare is not considered for price fixation.

Computation of Retail Price based on Aug, 2023 Data under Para 5 of DPCO, 2013

Dapagliflozin 10mg	Number of Companies consisting of Market Share of 1% & Above					19
	Sum of MAT value considered for price calculation (In Lakhs)					32,020.70
	Sum of PTR per unit considered for price calculation					269.56
	Number of Packs considered					26
	Average PTR					10.37
	Add : 16% Retailer Margin					1.66
	Retail Price (without local taxes)					12.03
	% Reduction with compared to Highest Price					36.88%

Minimum Price (Rs.)			4.21
Maximum Price (Rs.)			16.43
Average of all considered (Rs.)			10.37
Retail Price (Rs.)			12.03

S.No.	पैक विवरण Pack Description	ब्रांड BRAND	कंपनी Company	Strength	Pack Size	Unit	TOTAL MAT PTR (Rs.)	3,56,92,19,032 MAT(Rs.)	100% SKU wise MAT %	Brandwise MAT (Ignoring 0% MAT)	Qualify (Y/N) Y=Yes N=No	M3 Price per Unit (Rs.)	Price per Unit (Rs.) Considered
1	4 DAPA 10 MG TABLET 10	4 DAPA	4 CARE LIFESCIENCE PVT LTD	10 MG	10	TABLET	85	1271940.00	0.04%	0.04%	N	8.50	
2	4 DAPA M 10 MG TABLET 10	4 DAPA M	4 CARE LIFESCIENCE PVT LTD	10 MG	10	TABLET	100	34800.00	0.00%	0.00%	N	10.00	
3	GLEDEPA 10 MG TABLET 14	GLEDEPA	ABBOTT HEALTHCARE PVT. LTD	10 MG	14	TABLET	573.5						
4	GLUJECT 10 MG TABLET 15	GLUJECT	ABBOTT HEALTHCARE PVT. LTD	10 MG	15	TABLET	160.71						
5	LVEFFECT 10 MG TABLET 15	LVEFFECT	ABBOTT HEALTHCARE PVT. LTD	10 MG	15	TABLET	160.71						
6	DAXIGA 10 MG TABLET 10	DAXIGA	ACMEDIX PHARMA LLP	10 MG	10	TABLET	49.29	10150289.70	0.28%	0.28%	N	4.93	
7	DAPALEX 10 MG TABLET 10	DAPALEX	AJANTA PHARMA LTD	10 MG	10	TABLET	117.86	16501140.22	0.46%	0.46%	N	11.79	
8	DAPALEX 10 MG TABLET 15	DAPALEX	AJANTA PHARMA LTD	10 MG	15	TABLET	165.71	12217632.59	0.34%	0.34%	N	11.05	
9	DAPANTA 10 MG TABLET 10	DAPANTA	AJANTA PHARMA LTD	10 MG	10	TABLET	38.4	258470.40	0.01%	0.01%	N	3.84	
10	DAPASIS 10 MG TABLET 10	DAPASIS	AKESISS PHARMA (P) LTD	10 MG	10	TABLET	109.07	13437751.21	0.38%	0.38%	N	10.91	
11	SWITDAPA 10 MG TABLET 10	SWITDAPA	AKUMENTIS HEALTHCARE LTD	10 MG	10	TABLET	85	10925645.00	0.31%	0.31%	N	8.50	
12	VOAGE 10 MG TABLET 10	VOAGE	ALEMBIC LTD	10 MG	10	TABLET	84.78	73905579.96	2.07%	2.07%	Y	8.48	8.48
13	DAPANORM 10 MG TABLET 10	DAPANORM	ALKEM LABORATORIES LTD.	10 MG	10	TABLET	125	302071750.00	8.46%	8.46%	Y	12.50	12.50
14	FLOZIMAX 10 MG TABLET 15	FLOZIMAX	ALNICHE LIFE SCIENCES PVT.LTD	10 MG	15	TABLET	139.29	2245494.09	0.06%	0.06%	N	9.29	
15	DAPAZOL 10 MG TABLET 10	DAPAZOL	ALTEUS BIOGENICS PVT.LTD.	10 MG	10	TABLET	106.07	964176.30	0.03%	0.03%	N	10.61	
16	DAPAYES 10 MG TABLET 10	DAPAYES	ANAX LIFE SCIENCES PVT.LTD	10 MG	10	TABLET	71.43	39043.33	0.00%	0.00%	N	7.14	
17	DAPATREND 10 MG TABLET 14	DAPATREND	ANTHEM BIOPHARMA PVT LTD	10 MG	14	TABLET	117.86	4168708.20	0.12%	0.12%	N	8.42	
18	DINECA 10 MG TABLET 14	DINECA	APOSTLE REMEDIES	10 MG	14	TABLET	100	207500.00	0.01%	0.01%	N	7.14	
19	DAPRICA 10 MG TABLET 10	DAPRICA	APRICA HEALTHCARE PVT LTD	10 MG	10	TABLET	111.86	11266091.76	0.32%	0.32%	N	11.18	
20	GLUFLOZIN 10 MG TABLET 15	GLUFLOZIN	ARISTO PHARMACEUTICALS PVT.LTD	10 MG	15	TABLET	114.29	43408586.10	1.22%	1.22%	Y	7.62	7.62
21	FORXIGA 10 MG TABLET 14	FORXIGA	ASTRAZENCA PHARMA INDIA LTD	10 MG	14	TABLET	330						
22	PROGVIN 10 MG TABLET 10	PROGVIN	AVIN PHARMACEUTICALS	10 MG	10	TABLET	104.4	5637.60	0.00%	0.00%	N	10.44	
23	DAPATEN 10 MG TABLET 15	DAPATEN	BAL PHARMA	10 MG	15	TABLET	117.54	502601.04	0.01%	0.01%	N	7.84	
24	BIOXIGA 10 MG TABLET 10	BIOXIGA	BIOS LAB PVT.LTD	10 MG	10	TABLET	102.85	2136623.68	0.06%	0.06%	N	10.29	
25	DIABIZ (BLUE) 10 MG TABLET 15	DIABIZ (BLUE)	BLUE CROSS LABORATORIES LTD	10 MG	15	TABLET	75	12601425.00	0.35%	0.35%	N	5.00	
26	DAPADEL 10 MG TABLET 10	DAPADEL	CADELL HEALTH CARE PVT.LTD	10 MG	10	TABLET	92.14	3159019.90	0.09%	0.09%	N	9.21	
27	ZANELLA 10 MG TABLET 10	ZANELLA	CADOMED PHARMACEUTICALS INDIA PVT.L	10 MG	10	TABLET	79.07	1531111.48	0.04%	0.04%	N	7.91	
28	DAPASACH 10 MG TABLET 10	DAPASACH	CIPLA LTD.	10 MG	10	TABLET	71.43	9330043.74	0.26%	0.26%	N	7.14	
29	GLIFDAPA 10 MG TABLET 10	GLIFDAPA	CNR LIFE SCIENCES	10 MG	10	TABLET	96.43	127287.60	0.00%	0.00%	N	9.64	
30	DAPABITE 10 MG TABLET 10	DAPABITE	CORONA	10 MG	10	TABLET	128.75	95225438.83	2.67%	2.67%	Y	12.88	12.88
31	DIOGLT 10 MG TABLET 15	DIOGLT	DIOS LIFESCIENCES PRIVATE LIMITED	10 MG	15	TABLET	147.32	430370.14	0.01%	0.01%	N	9.82	
32	DAPLO 10 MG TABLET 10	DAPLO	DR. REDDY'S LABORATORIES LTD	10 MG	10	TABLET	129.64	99220746.50	2.78%	2.78%	Y	12.96	12.96

33	ESGEDAP 10 MG TABLET 14	ESGEDAP	EAST WEST PHARMA	10 MG	14	TABLET	159.5	1285679.11	0.04%	0.04%	N	11.39	
34	DAPACOL 10 MG TABLET 10	DAPACOL	ECON HEALTHCARE PVT LTD	10 MG	10	TABLET	78.57	27578.07	0.00%	0.00%	N	7.88	
35	DAPADER 10 MG TABLET 14	DAPADER	ELDER PHARMACEUTICALS LTD	10 MG	14	TABLET	63.43	14779.19	0.00%	0.00%	N	4.53	
36	ELDAPA 10 MG TABLET 10	ELDAPA	EL-DORADO BIO-TECH PVT LTD	10 MG	10	TABLET	71.43	183932.25	0.01%	0.01%	N	7.14	
37	XGLET 10 MG TABLET 10	XGLET	ELINOR PHARMA	10 MG	10	TABLET	140	331800.00	0.01%	0.01%	N	14.00	
38	DAPAGZA 10 MG TABLET 15	DAPAGZA	EMCURE PHARMACEUTICALS LTD	10 MG	15	TABLET	159.64	456896.80	0.13%	0.13%	N	10.64	
39	EMILDAP 10 MG TABLET 15	EMILDAP	EMCURE PHARMACEUTICALS LTD	10 MG	15	TABLET	159.64	22111736.40	0.62%	0.62%	N	10.64	
40	DAPAZEP 10 MG TABLET 10	DAPAZEP	ERGOS LIFE SCIENCES	10 MG	10	TABLET	85.71	242302.17	0.01%	0.01%	N	8.57	
41	MYODA 10 MG TABLET 10	MYODA	ERIS LIFESCIENCES LTD	10 MG	10	TABLET	113.93	7733568.40	0.22%	0.22%	N	11.39	
42	GLUKIT 10 MG TABLET 10	GLUKIT	ERIS LIFESCIENCES LTD	10 MG	10	TABLET	108.75	270523444.48	7.58%	7.58%	Y	10.88	10.88
43	DIFLUP 10 MG TABLET 10	DIFLUP	EXELTIS	10 MG	10	TABLET	110.71	978233.56	0.03%	0.03%	N	11.07	
44	DIABFLOZ 10 MG TABLET 10	DIABFLOZ	FINECURE PHARMACEUTICALS	10 MG	10	TABLET	82.14	62919.53	0.00%	0.00%	N	8.21	
45	FLOZIDAP 10 MG TABLET 10	FLOZIDAP	FRANCO INDIAN PHARMACEUTICALS PVT LTD	10 MG	10	TABLET	103.57	2858428.43	0.08%	0.08%	N	10.38	
46	DEXIGLU 10 MG TABLET 10	DEXIGLU	FUSION HEALTHCARE PVT LTD	10 MG	10	TABLET	114.29	25542642.80	0.72%	0.72%	N	11.43	
47	DAPA GOLD 10 MG TABLET 15	DAPA GOLD	HBC LIFESCIENCES PVT LTD	10 MG	15	TABLET	159.64	14115007.08	0.40%	0.40%	N	10.64	
48	DAPADOT 10 MG TABLET 10	DAPADOT	HETERO HEALTHCARE LTD	10 MG	10	TABLET	103.57	741354.06	0.02%	0.02%	N	10.36	
49	DAPARAY 10 MG TABLET 10	DAPARAY	ICON LIFESCIENCES	10 MG	10	TABLET	75.71	2143425.81	0.06%	0.06%	N	7.57	
50	DIGLUZ 10 MG TABLET 10	DIGLUZ	INDCHEMIE HEALTH SPECIALITIES PVT. LTD.	10 MG	10	TABLET	99.29	5361.66	0.00%	0.00%	N	9.93	
51	DIMPRIDE 10 MG TABLET 10	DIMPRIDE	INDCHEMIE HEALTH SPECIALITIES PVT. LTD.	10 MG	10	TABLET	99.29	1231508.04	0.03%	0.03%	N	9.93	
52	DEPAJA 10 MG TABLET 10	DEPAJA	INDOCO REMEDIES LTD	10 MG	10	TABLET	82.14	148591.26	0.00%	0.00%	N	8.21	
53	DAPARYL 10 MG TABLET 10	DAPARYL	INTAS PHARMACEUTICALS LTD	10 MG	10	TABLET	101.43	231823131.49	6.50%	6.50%	Y	10.14	10.14
54	DAPAVEL 10 MG TABLET 10	DAPAVEL	INTAS PHARMACEUTICALS LTD	10 MG	10	TABLET	101.43	347218058.05	9.73%	9.73%	Y	10.14	10.14
55	T2C 10 MG TABLET 15	T2C	IPCA LABORATORIES PVT LTD.	10 MG	15	TABLET	200.29	21723678.38	0.61%	0.61%	N	13.35	
56	DAPABLESS 10 MG TABLET 10	DAPABLESS	JAGSONPAL PHARMACEUTICALS LTD	10 MG	10	TABLET	50	43350.00	0.00%	0.00%	N	5.00	
57	JODAPA 10 MG TABLET 15	JODAPA	JARUN PHARMACEUTICALS	10 MG	15	TABLET	117.86	732705.74	0.02%	0.02%	N	7.86	
58	DAPACOSE 10 MG TABLET 10	DAPACOSE	JB CHEMICALS	10 MG	10	TABLET	103.62	49299819.66	1.38%	1.38%	Y	10.36	10.36
59	DAPAEASE 10 MG TABLET 10	DAPAEASE	JUBILANT GENERICS LIMITED	10 MG	10	TABLET	103.57	1706937.17	0.05%	0.05%	N	10.36	
60	DAPAEASE V 10 MG TABLET SR 15	DAPAEASE V	JUBILANT GENERICS LIMITED	10 MG	15	TABLET SR	135	2752785.00	0.08%	0.08%	N	9.00	
61	DEGUFLU 10 MG TABLET 10	DEGUFLU	KANAD LABS	10 MG	10	TABLET	203.39	220474.76	0.01%	0.01%	N	20.34	
62	DMBEST 10 MG TABLET 10	DMBEST	KEPLER HEALTH CARE	10 MG	10	TABLET	92.86	1260203.06	0.04%	0.04%	N	9.29	
63	DAGLIPACK 10 MG TABLET 10	DAGLIPACK	KOYE PHARMACEUTICALS PVT. LTD.	10 MG	10	TABLET	99.29	5124456.19	0.14%	0.14%	N	9.93	
64	DAPACONIC 10 MG TABLET 15	DAPACONIC	LA RENON	10 MG	15	TABLET	198.57	5952471.10	0.17%	0.17%	N	13.24	
65	DAPAHENZ 10 MG TABLET 15	DAPAHENZ	LA RENON	10 MG	15	TABLET	198.57	35284300.44	0.99%	0.99%	N	13.24	
66	DAPAFORD 10 MG TABLET 15	DAPAFORD	LEEFOOD HEALTHCARE	10 MG	15	TABLET	45	16290.00	0.00%	0.00%	N	3.00	
67	DIFOZIN 10 MG TABLET 14	DIFOZIN	LINCOLN PHARMACEUTICALS LTD	10 MG	14	TABLET	149.29	166906.22	0.00%	0.00%	N	10.66	
68	SUGAFLO 10 MG TABLET 15	SUGAFLO	LLOYD HEALTHCARE PVT. LTD	10 MG	15	TABLET	176.8	20918488.08	0.59%	0.59%	N	11.79	
69	DAPATURN 10 MG TABLET 10	DAPATURN	LUPIN LTD	10 MG	10	TABLET	113.86	53482168.63	1.50%	1.50%	Y	11.39	11.39
70	DAMITA 10 MG TABLET 10	DAMITA	MACLEODS PHARMACEUTICALS PVT. LTD	10 MG	10	TABLET	117.07	88963547.82	2.49%	2.49%	Y	11.71	11.71
71	DAPAMAC 10 MG TABLET 10	DAPAMAC	MACLEODS PHARMACEUTICALS PVT. LTD	10 MG	10	TABLET	117.07	179160465.55	5.02%	5.02%	Y	11.71	11.71
72	JUSTOZA 10 MG TABLET 10	JUSTOZA	MANKIND PHARMACEUTICALS LTD.	10 MG	10	TABLET	70.71	22617795.57	0.63%	1.84%	Y	7.07	7.07
73	JUSTOZA 10 MG TABLET 15	JUSTOZA	MANKIND PHARMACEUTICALS LTD.	10 MG	15	TABLET	106.07	36108349.40	1.01%	1.84%	Y	7.07	7.07
74	SGLTD 10 MG TABLET 10	SGLTD	MANKIND PHARMACEUTICALS LTD.	10 MG	10	TABLET	70.71	64757137.23	1.81%	1.81%	Y	7.07	7.07
75	DAPABLI 10 MG TABLET 10	DAPABLI	MED MANOR ORGANICS PVT LTD.	10 MG	10	TABLET	90	1748314.74	0.05%	0.05%	N	9.00	
76	DAPANOVA 10 MG TABLET 15	DAPANOVA	MEDLEY PHARMACEUTICALS	10 MG	15	TABLET	153.57	44936594.58	1.26%	1.26%	Y	10.24	10.24
77	ZUCAPRIDE 10 MG TABLET 15	ZUCAPRIDE	MICRO LABS LTD	10 MG	15	TABLET	151.43	97415446.62	2.73%	2.73%	Y	10.10	10.10
78	DAIJO 10 MG TABLET 15	DAIJO	MICRO LABS LTD	10 MG	15	TABLET	137.86	48552499.82	1.36%	1.36%	Y	9.19	9.19
79	VIVADAPA 10 MG TABLET 10	VIVADAPA	MITOCH PHARMA PVT LTD	10 MG	10	TABLET	100	16240400.00	0.46%	0.46%	N	10.00	
80	DAPACONE 10 MG TABLET 10	DAPACONE	MSN LABORATORIES LTD	10 MG	10	TABLET	117.64	36843983.00	1.03%	1.03%	Y	11.76	11.76
81	DAPNAT 10 MG TABLET 10	DAPNAT	NATCO PHARMA LTD	10 MG	10	TABLET	70.71	2774236.14	0.08%	2.19%	Y	7.07	7.07
82	DAPNAT 10 MG TABLET 30	DAPNAT	NATCO PHARMA LTD	10 MG	30	TABLET	492.86	75207156.82	2.11%	2.19%	Y	16.43	16.43
83	DAPACARE 10 MG TABLET 10	DAPACARE	OCTALIFE PHARMACEUTICALS PVT. LTD	10 MG	10	TABLET	64.29	259375.55	0.01%	0.01%	N	6.43	
84	OPSICA 10 MG TABLET 15	OPSICA	OPSISCARE LIFESCIENCE PVT LTD	10 MG	15	TABLET	150	1295250.00	0.04%	0.04%	N	10.00	
85	OZODAP 10 MG TABLET 15	OZODAP	OZONE PHARMACEUTICALS	10 MG	15	TABLET	53.57	820799.54	0.02%	0.02%	N	3.57	
86	DAPABEST 10 MG TABLET 10	DAPABEST	PANACEA BIOTEC LTD	10 MG	10	TABLET	88.56	669611.12	0.02%	0.02%	N	8.86	
87	DAPAKY 10 MG TABLET 10	DAPAKY	PRECIA PHARMA	10 MG	10	TABLET	103.57	4458274.22	0.12%	0.12%	N	10.36	
88	GLUFOPRIME 10 MG TABLET 10	GLUFOPRIME	PRIMUS REMEDIES PVT LTD	10 MG	10	TABLET	62.5	4249964.83	0.12%	0.12%	N	6.25	
89	DPO 10 MG TABLET 10	DPO	RPG LIFE SCIENCES LTD.	10 MG	10	TABLET	85.71	3001392.78	0.08%	0.08%	N	8.57	
90	DAPASAN 10 MG TABLET 14	DAPASAN	SANATRA HEALTH CARE PVT. LTD	10 MG	14	TABLET	157.14	569474.76	0.02%	0.02%	N	11.22	
91	SHIDAPA 10 MG TABLET 10	SHIDAPA	SHINE PHARMACEUTICALS LTD	10 MG	10	TABLET	85.71	48834.70	0.00%	0.00%	N	8.57	

92	DAPASIG 10 MG TABLET 10	DAPASIG	SIGNOVA PHARMA (P) LTD	10 MG	10	TABLET	84.29	226824.39	0.01%	0.01%	N	8.43	
93	MDAPA 10 10 MG TABLET 10	MDAPA 10	SINSAN PHARMACEUTICALS	10 MG	10	TABLET	96.43	434320.72	0.01%	0.01%	N	9.64	
94	MDAPA 10 10 MG TABLET 15	MDAPA 10	SINSAN PHARMACEUTICALS	10 MG	15	TABLET	96.43	102022.94	0.00%	0.00%	N	6.43	
95	DAPAGREAT 10 MG TABLET 15	DAPAGREAT	SINSAN PHARMACEUTICALS	10 MG	15	TABLET	150	63678.72	0.00%	0.00%	N	10.00	
96	DAPASPEC 10 MG TABLET 10	DAPASPEC	SPECTRA THERAPEUTICS PVT. LTD.	10 MG	10	TABLET	96.43	3571574.34	0.10%	0.10%	N	9.64	
97	OXRA 10 MG TABLET 14	OXRA	SUN PHARMA LABORATORIES LTD.	10 MG	14	TABLET	141.43						
98	DAPEFY 10 MG TABLET 14	DAPEFY	SUN PHARMA LABORATORIES LTD.	10 MG	14	TABLET	141.43						
99	DAPAGAIN 10 MG TABLET 15	DAPAGAIN	SYSTOPIC LABORATORIES LTD-MEM	10 MG	15	TABLET	63.22	53801041.86	1.51%	1.51%	Y	4.21	4.21
100	DAPIXA 10 MG TABLET 10	DAPIXA	TAS MED (INDIA) PRIVATE LTD.	10 MG	10	TABLET	110	2159300.00	0.06%	0.06%	N	11.00	
101	GLUCRETA 10 MG TABLET 10	GLUCRETA	TORRENT PHARMACEUTICALS LTD.	10 MG	10	TABLET	97.71	174466865.19	4.89%	4.89%	Y	9.77	9.77
102	DGSON 10 MG TABLET 10	DGSON	UNISON PHARMACEUTICALS	10 MG	10	TABLET	32.14	10568981.88	0.30%	0.30%	N	3.21	
103	UDAPA 10 MG TABLET 10	UDAPA	USV PVT LTD	10 MG	10	TABLET	94.29	470189248.41	13.17%	13.17%	Y	9.43	9.43
104	DAPAVAS 10 MG TABLET 10	DAPAVAS	VASU ORGANICS PVT.LTD	10 MG	10	TABLET	91.93	69189.19	0.00%	0.00%	N	9.19	
105	FLOZIPA 10 MG TABLET 10	FLOZIPA	WALLACE PHARMACEUTICALS LTD.	10 MG	10	TABLET	100	6116900.00	0.17%	0.17%	N	10.00	
106	ZINODAP 10 MG TABLET 10	ZINODAP	WOCKHARDT LTD	10 MG	10	TABLET	113.57	14942859.18	0.42%	0.42%	N	11.35	
107	DAPASET 10 MG TABLET 14	DAPASET	WONSET HEALTH CARE PRIVATE LIMITED	10 MG	14	TABLET	103.57	304748.69	0.01%	0.01%	N	7.40	
108	DAPAFOR 10 MG TABLET 10	DAPAFOR	ZUVENTUS HEALTHCARE LTD	10 MG	10	TABLET	75	1482900.00	0.04%	0.04%	N	7.50	
109	DAPAGLYN 10 MG TABLET 10	DAPAGLYN	ZYDUS CADILA - ZHL	10 MG	10	TABLET	146.93	6896013.38	0.19%	6.72%	Y	14.69	14.69
110	DAPAGLYN 10 MG TABLET 15	DAPAGLYN	ZYDUS CADILA - ZHL	10 MG	15	TABLET	220.39	233201320.06	6.53%	6.72%	Y	14.69	14.69
		Rs. Per tablet											
	Worked out Retail Price	12.03	Excluding GST										

Note: In view of DPCO Amendment Vide S.O. No. 2165(E) dated 11.05.2023, Patent Holder of Dapagliflozin i.e. M/s Astra Zeneca & License holder i.e. M/s Sun Pharma and M/s Abbott Healthcare is not considered for price fixation.

Linagliptin 5mg

Number of Companies consisting of Market Share of 1% & Above				8
Sum of MAT value considered for price calculation (in Lakhs)				2,541.84
Sum of PTR per unit considered for price calculation				87.25
Number of Packs considered				9
Average PTR				9.69
Add : 16% Retailer Margin				1.55
Retail Price (without local taxes)				11.24
% Reduction with compared to Highest Price				17.04%

Minimum Price (Rs.)			6.79
Maximum Price (Rs.)			11.68
Average of all considered (Rs.)			9.69
Retail Price (Rs.)			11.24

[illegible]

Note: In view of DPCO Amendment Vide S.O. No. 2165(E) dated 11.05.2023, Patent Holder of Linagliptin i.e. M/s Boehringer Ingelheim & License holder i.e. M/s Lupin Ltd, is not considered for price fixation.

Computation of Retail Price based on Aug. 2023 Data under Para 5 of DPCO, 2013

Dapagliflozin 10mg + Metformin 500mg	Number of Companies consisting of Market Share of 1% & Above						19
	Sum of MAT value considered for price calculation (in Lakhs)						10,577.88
	Sum of PTR per unit considered for price calculation						235.26
Number of Packs considered							26
Average PTR							9.05
Add : 16% Retailer Margin							1.45
Retail Price (without local taxes)							10.50
% Reduction with compared to Highest Price							38.35%

Minimum Price (Rs.)			5.00
Maximum Price (Rs.)			14.68
Average of all considered (Rs.)			9.05
Retail Price (Rs.)			10.5

S.No.	पैक विवरण Pack Description	उप BRAND	कंपनी Company	Strength	Pack Size	Unit	TOTAL MAT		SKU wise MAT %	Brandwise MAT (ignoring 0% MAT)	Qualify (Y/N) Y=Yes N=No	M3 Price per Unit (Rs.)	Price per Unit (Rs.) Considered
							PTR (Rs.)	MAT(Rs.)					
1	GLEDEPA MET 10/500 MG TABLET XR 7	GLEDEPA MET	ABBOTT HEALTHCARE PVT. LTD	10/500 MG	7	TABLET XR	312.14						
2	GLUJECT M 10/500 MG TABLET 15	GLUJECT M	ABBOTT HEALTHCARE PVT. LTD	10/500 MG	15	TABLET	111.24						
3	GLUJECT TRIO 10/500 MG TABLET 10	GLUJECT TRIO	ABBOTT HEALTHCARE PVT. LTD	10/500 MG	10	TABLET	157.11						
4	DAXIGA M 10/500 MG TABLET 10	DAXIGA M	ACMEDIX PHARMA LLP	10/500 MG	10	TABLET	41.43	2531538.72	0.22%	0.22%	N	4.14	
5	DAPALEX M 10/500 MG TABLET 10	DAPALEX M	AJANTA PHARMA LTD	10/500 MG	10	TABLET	117.86	13780544.78	1.20%	1.20%	Y	11.78	11.78
6	DAPANTA M 10/500 MG TABLET 10	DAPANTA M	AJANTA PHARMA LTD	10/500 MG	10	TABLET	45.6	206096.40	0.02%	0.02%	N	4.56	
7	DAPASIS M 10/500 MG TABLET ER 10	DAPASIS M	AKESISS PHARMA (P) LTD	10/500 MG	10	TABLET ER	77.85	5530588.80	0.48%	0.48%	N	7.78	
8	SWITDAPA M 10/500 MG TABLET XR 10	SWITDAPA M	AKUMENTIS HEALTHCARE LTD	10/500 MG	10	TABLET XR	85	3985905.00	0.35%	0.35%	N	8.50	
9	VOAGE M 10/500 MG TABLET 10	VOAGE M	ALEMBIC LTD	10/500 MG	10	TABLET	93.36	29526382.88	2.58%	2.58%	Y	9.34	9.34
10	DAPANORM M 10/500 MG TABLET 10	DAPANORM M	ALKEM LABORATORIES LTD.	10/500 MG	10	TABLET	97.86	89790231.27	7.83%	7.83%	Y	9.79	9.78
11	DAPAZOL M 10/500 MG TABLET 10	DAPAZOL M	ALTEUS BIOGENICS PVT.LTD.	10/500 MG	10	TABLET	109.2	382799.56	0.03%	0.03%	N	10.92	
12	DAPAYES M 10/500 MG TABLET 10	DAPAYES M	ANAX LIFE SCIENCES PVT.LTD	10/500 MG	10	TABLET	78.57	90591.21	0.01%	0.01%	N	7.86	
13	DAPATREND M 10/500 MG TABLET 10	DAPATREND M	ANTHEM BIOPHARMA PVT LTD	10/500 MG	10	TABLET	76.64	1977235.36	0.17%	0.17%	N	7.66	
14	CIDIDAP M 10/500 MG TABLET 10	CIDIDAP M	APEX LABORATORIES LTD.	10/500 MG	10	TABLET	72.86	1063756.00	0.09%	0.09%	N	7.29	
15	DINECA M 10/500 MG TABLET 10	DINECA M	APOSTLE REMEDIES	10/500 MG	10	TABLET	54.29	61836.31	0.01%	0.01%	N	5.43	
16	DAPRICA M 10/500 MG TABLET 10	DAPRICA M	APRICA HEALTHCARE PVT LTD	10/500 MG	10	TABLET	91.03	1986183.57	0.17%	0.17%	N	9.10	
17	GLUTUS M 10/500 MG TABLET 10	GLUTUS M	ARETAUS PHARMACEUTICALS	10/500 MG	10	TABLET	79.64	722255.16	0.06%	0.06%	N	7.96	
18	GLUFLOZIN MF 10/500 MG TABLET 15	GLUFLOZIN MF	ARISTO PHARMACEUTICALS PVT.LTD	10/500 MG	15	TABLET	115.71	9145718.40	0.80%	0.80%	N	7.71	
19	XIGDUO 10/500 MG TABLET XR 7	XIGDUO	ASTRAZENECA PHARMA INDIA LTD	10/500 MG	7	TABLET XR	348.57						
20	PROGVIN M 10/500 MG TABLET 10	PROGVIN M	AVIN PHARMACEUTICALS	10/500 MG	10	TABLET	114.3	4800.60	0.00%	0.00%	N	11.43	
21	DAPATEN M 10/500 MG TABLET 15	DAPATEN M	BAL PHARMA	10/500 MG	15	TABLET	119.68	431565.08	0.04%	0.04%	N	7.98	
22	BIOXIGA M 10/500 MG TABLET 10	BIOXIGA M	BIOS LAB PVT.LTD	10/500 MG	10	TABLET	102.85	41315.46	0.00%	0.00%	N	10.29	
23	DIABIZ M 10/500 MG TABLET 15	DIABIZ M	BLUE CROSS LABORATORIES LTD	10/500 MG	15	TABLET	96.43	4263073.87	0.37%	0.37%	N	6.43	
24	DAPADEL M 10/500 MG TABLET 10	DAPADEL M	CADELL HEALTH CARE PVT.LTD	10/500 MG	10	TABLET	106.43	683174.17	0.06%	0.06%	N	10.64	
25	ZANELLA M 10/500 MG TABLET 10	ZANELLA M	CADOMED PHARMACEUTICALS INDIA PVT.L	10/500 MG	10	TABLET	86.91	250735.35	0.02%	0.02%	N	8.69	
26	DAPASACH M 10/500 MG TABLET 10	DAPASACH M	CIPLA LTD.	10/500 MG	10	TABLET	73.68	3853906.08	0.34%	0.34%	N	7.37	
27	GLIFDAPA M 10/500 MG TABLET 10	GLIFDAPA M	CMR LIFE SCIENCES	10/500 MG	10	TABLET	81.43	21823.24	0.00%	0.00%	N	8.14	
28	DAPABITE M 10/500 MG TABLET 10	DAPABITE M	CORONA	10/500 MG	10	TABLET	102.57	36854041.56	3.21%	3.21%	Y	10.26	10.26
29	DAPLO M 10/500 MG TABLET 10	DAPLO M	DR. REDDYS LABORATORIES LTD	10/500 MG	10	TABLET	146.78	33722861.51	2.94%	2.94%	Y	14.68	14.68
30	DAPAGZA M 10/500 MG TABLET 10	DAPAGZA M	EMCURE PHARMACEUTICALS LTD	10/500 MG	10	TABLET	73.43	1640426.20	0.14%	0.14%	N	7.34	
31	EMILDAP M 10/500 MG TABLET 10	EMILDAP M	EMCURE PHARMACEUTICALS LTD	10/500 MG	10	TABLET	73.43	7562482.27	0.66%	0.66%	N	7.34	
32	DAPAZEP M 10/500 MG TABLET 10	DAPAZEP M	ERGOS LIFE SCIENCES	10/500 MG	10	TABLET	71.43	272219.73	0.02%	0.02%	N	7.14	

33	GLUXIT M 10/500 MG TABLET 10	GLUXIT M	ERIS LIFESCIENCES LTD	10/500 MG	10	TABLET	98.92	51510546.81	4.49%	4.49%	Y	9.89	9.89
34	DEXIGLU M 10/500 MG TABLET 10	DEXIGLU M	FUSION HEALTHCARE PVT LTD	10/500 MG	10	TABLET	83.57	11894203.18	1.04%	1.04%	Y	8.36	8.36
35	DAPA GOLD M 10/500 MG TABLET 15	DAPA GOLD M	HBC LIFESCIENCES PVT LTD	10/500 MG	15	TABLET	92.86	13130346.68	1.15%	1.15%	Y	6.19	6.19
36	DAPARAY M 10/500 MG TABLET 10	DAPARAY M	ICON LIFESCIENCES	10/500 MG	10	TABLET	84.29	163185.76	0.01%	0.01%	N	8.43	
37	DIGLIZ M 10/500 MG TABLET 10	DIGLIZ M	INDICHEMIE HEALTH SPECIALITIES PVT. LTD.	10/500 MG	10	TABLET	89.29	5357.40	0.00%	0.00%	N	8.93	
38	DIMPRIDE M 10/500 MG TABLET 10	DIMPRIDE M	INDICHEMIE HEALTH SPECIALITIES PVT. LTD.	10/500 MG	10	TABLET	81.76	1090514.88	0.10%	0.10%	N	8.18	
39	DAPARYL M 10/500 MG TABLET 10	DAPARYL M	INTAS PHARMACEUTICALS LTD	10/500 MG	10	TABLET	97.86	48454570.68	4.23%	4.23%	Y	9.79	9.79
40	DAPAVEL M 10/500 MG TABLET 10	DAPAVEL M	INTAS PHARMACEUTICALS LTD	10/500 MG	10	TABLET	97.85	58614858.30	5.11%	5.11%	Y	9.79	9.79
41	T2C M 10/500 MG TABLET 15	T2C M	IPCA LABORATORIES PVT LTD.	10/500 MG	15	TABLET	127.32	3561707.73	0.31%	0.31%	N	8.49	
42	JODAPA M 10/500 MG TABLET 15	JODAPA M	JARUN PHARMACEUTICALS	10/500 MG	15	TABLET	135.71	153454.56	0.01%	0.01%	N	9.05	
43	DAPACOSE M 10/500 MG TABLET 10	DAPACOSE M	JB CHEMICALS	10/500 MG	10	TABLET	86.02	11479597.70	1.00%	1.00%	Y	8.60	8.60
44	DAPAEASE M 10/500 MG TABLET 10	DAPAEASE M	JUBILANT GENERICS LIMITED	10/500 MG	10	TABLET	72.78	409871.10	0.04%	0.04%	N	7.28	
45	DEGLIFLO M 10/500 MG TABLET 10	DEGLIFLO M	KANAD LABS	10/500 MG	10	TABLET	85.71	45512.01	0.00%	0.00%	N	8.57	
46	DMBEST M 10/500 MG TABLET 10	DMBEST M	KEPLER HEALTH CARE	10/500 MG	10	TABLET	76.43	655162.86	0.06%	0.06%	N	7.64	
47	DAGUPACK M 10/500 MG TABLET 10	DAGUPACK M	KOYE PHARMACEUTICALS PVT. LTD.	10/500 MG	10	TABLET	99.29	637441.80	0.06%	0.06%	N	9.93	
48	DAPAHENZ M 10/500 MG TABLET 10	DAPAHENZ M	LA RENON	10/500 MG	10	TABLET	120.71	5607182.56	0.58%	0.58%	N	12.07	
49	DAPAFORD M 10/500 MG TABLET 15	DAPAFORD M	LEEFORD HEALTHCARE	10/500 MG	15	TABLET	69	447196.20	0.04%	0.04%	N	4.60	
50	DIFOZIN M 10/500 MG TABLET 10	DIFOZIN M	LINCOLN PHARMACEUTICALS LTD	10/500 MG	10	TABLET	84.29	39784.88	0.00%	0.00%	N	8.43	
51	SUGAFLO M 10/500 MG TABLET 15	SUGAFLO M	LLOYD HEALTHCARE PVT.LTD	10/500 MG	15	TABLET	139.79	4451109.84	0.39%	0.39%	N	9.32	
52	DAPATURN M 10/500 MG TABLET 10	DAPATURN M	LUPIN LTD	10/500 MG	10	TABLET	84.86	18296751.82	1.60%	1.60%	Y	8.49	8.49
53	DAMITA M 10/500 MG TABLET 10	DAMITA M	MACLEODS PHARMACEUTICALS PVT.LTD	10/500 MG	10	TABLET	50	16072433.59	1.40%	1.67%	Y	5.00	5.00
54	DAMITA M 10/500 MG TABLET 15	DAMITA M	MACLEODS PHARMACEUTICALS PVT.LTD	10/500 MG	15	TABLET	111.23	3098724.30	0.27%	1.67%	Y	7.42	7.42
55	DAPAMAC M 10/500 MG TABLET 10	DAPAMAC M	MACLEODS PHARMACEUTICALS PVT.LTD	10/500 MG	10	TABLET	81.71	2876273.71	0.25%	4.62%	Y	8.17	8.17
56	DAPAMAC M 10/500 MG TABLET 15	DAPAMAC M	MACLEODS PHARMACEUTICALS PVT.LTD	10/500 MG	15	TABLET	111.23	50047362.19	4.37%	4.62%	Y	7.42	7.42
57	JUSTOZA M 10/500 MG TABLET 10	JUSTOZA M	MANKIND PHARMACEUTICALS LTD.	10/500 MG	10	TABLET	78.24	38916810.72	3.39%	6.24%	Y	7.82	7.82
58	JUSTOZA M 10/500 MG TABLET 15	JUSTOZA M	MANKIND PHARMACEUTICALS LTD.	10/500 MG	15	TABLET	117.35	32628815.45	2.85%	6.24%	Y	7.82	7.82
59	SGLTD M 10/500 MG TABLET 10	SGLTD M	MANKIND PHARMACEUTICALS LTD.	10/500 MG	10	TABLET	78.24	34736447.52	3.03%	3.03%	Y	7.82	7.82
60	DAPABUS M 10/500 MG TABLET 10	DAPABUS M	MED MANOR ORGANICS PVT LTD.	10/500 MG	10	TABLET	84.29	39953.46	0.00%	0.00%	N	8.43	
61	DAPANOVA M 10/500 MG TABLET 15	DAPANOVA M	MEDLEY PHARMACEUTICALS	10/500 MG	15	TABLET	181.07	12026669.40	1.05%	1.05%	Y	12.07	12.07
62	ZUCAPRIDE M 10/500 MG TABLET 10	ZUCAPRIDE M	MICRO LABS LTD	10/500 MG	10	TABLET	109.29	91690238.09	8.00%	8.00%	Y	10.93	10.93
63	DAJIO M 10/500 MG TABLET 10	DAJIO M	MICRO LABS LTD	10/500 MG	10	TABLET	100	27008645.35	2.36%	2.36%	Y	10.00	10.00
64	DAPAONE M 10/500 MG TABLET 10	DAPAONE M	MSN LABORATORIES LTD	10/500 MG	10	TABLET	91	6823355.42	0.60%	0.60%	N	9.10	
65	DAPABEST M 10/500 MG TABLET 10	DAPABEST M	PANACEA BIOTEC LTD	10/500 MG	10	TABLET	76.64	480379.52	0.04%	0.04%	N	7.68	
66	GLUFOPRIME M 10/500 MG TABLET 15	GLUFOPRIME M	PRIMUS REMEDIES PVT LTD	10/500 MG	15	TABLET	127.14	2806228.92	0.24%	0.24%	N	8.48	
67	DPO M 10/500 MG TABLET 10	DPO M	RPG LIFE SCIENCES LTD.	10/500 MG	10	TABLET	92.86	2533035.08	0.22%	0.22%	N	9.29	
68	DAPASPEC M 10/500 MG TABLET 10	DAPASPEC M	SPECTRA THERAPEUTICS PVT. LTD.	10/500 MG	10	TABLET	73.57	1038540.07	0.09%	0.09%	N	7.36	
69	OKRAMET 10/500 MG TABLET XR 7	OKRAMET	SUN PHARMA LABORATORIES LTD.	10/500 MG	7	TABLET XR	75						
70	DAPEFY M 10/500 MG TABLET XR 7	DAPEFY M	SUN PHARMA LABORATORIES LTD.	10/500 MG	7	TABLET XR	75						
71	DAPAGAIN M 10/500 MG TABLET 15	DAPAGAIN M	SYSTOPIC LABORATORIES LTD-MEM	10/500 MG	15	TABLET	84.64	13152802.08	1.15%	1.15%	Y	5.84	5.84
72	GLUCRETA M 10/500 MG TABLET 10	GLUCRETA M	TORRENT PHARMACEUTICALS LTD.	10/500 MG	10	TABLET	102	105801538.32	9.23%	9.23%	Y	10.20	10.20
73	DGSON M 10/500 MG TABLET 10	DGSON M	UNISON PHARMACEUTICALS	10/500 MG	10	TABLET	46.29	5417562.21	0.47%	0.47%	N	4.63	
74	UDAPA M 10/500 MG TABLET XR 10	UDAPA M	USV PVT LTD	10/500 MG	10	TABLET XR	89.93	143776306.94	12.54%	12.54%	Y	8.99	8.99
75	DAPAVAS M 10/500 MG TABLET 10	DAPAVAS M	VASU ORGANICS PVT.LTD	10/500 MG	10	TABLET	83.57	83319.29	0.01%	0.01%	N	8.36	
76	ZINODAP M 10/500 MG TABLET SR 15	ZINODAP M	WOCKHARDT LTD	10/500 MG	15	TABLET SR	119.76	3193280.64	0.28%	0.28%	N	7.98	
77	DIUTEN M 10/500 MG TABLET 15	DIUTEN M	WOCKHARDT LTD	10/500 MG	15	TABLET	119.76	3113.76	0.00%	0.00%	N	7.98	
78	DAPASET M 10/500 MG TABLET 10	DAPASET M	WONSET HEALTH CARE PRIVATE LIMITED	10/500 MG	10	TABLET	10	21630.00	0.00%	0.00%	N	1.00	
79	DAPAFORMIN 10/500 MG TABLET 10	DAPAFORMIN	ZUVENTUS HEALTHCARE LTD	10/500 MG	10	TABLET	82.14	1219532.58	0.11%	0.11%	N	8.21	
80	DAPAGLYN M 10/500 MG TABLET 15	DAPAGLYN M	ZYDUS CADILA - ZHL	10/500 MG	15	TABLET	134.89	68899518.87	6.01%	6.01%	Y	8.99	8.99
		Rs. Per tablet											
	Worked out Retail Price	10.50	Excluding GST										

Note: In view of DPCO Amendment Vide S.O. No. 2165(E) dated 11.05.2023, Patent Holder of Dapagliflozin i.e. M/s Astra Zeneca & License holder i.e. M/s Sun Pharma and M/s Abbott Healthcare is not considered for price fixation.

Computation of Retail Price based on Aug, 2023 Data under Para 5 of DPCO, 2013

Sitagliptin 100mg	Number of Companies consisting of Market Share of 1% & Above								20
	Sum of MAT value considered for price calculation (in Lakhs)								4,496.03
	Sum of PTR per unit considered for price calculation								231.58
	Number of Packs considered								25
	Average PTR								9.26
	Add : 16% Retailer Margin								1.48
	Retail Price (without local taxes)								10.74
	% Reduction with compared to Highest Price								22.38%

Minimum Price (Rs.)	5.71
Maximum Price (Rs.)	11.93
Average of all considered (Rs.)	9.26
Retail Price (Rs.)	10.74

S.No.	पैक विवरण Pack Description	छाप BRAND	कंपनी Company	Strength	Pack Size	Unit	TOTAL MAT		MAT (Rs.)	SKU wise MAT %	Brandwise MAT (ignoring O% MAT)	Quality (Y/N) Y=Yes N=No	Price per Unit (Rs.)	Price per Unit (Rs.) Considered
							PTR (Rs.)	49,98,15,109						
1	SIAGLIDE 100 MG TABLET 15	SIAGLIDE	ABBOTT HEALTHCARE PVT. LTD	100 MG	15	TABLET	178.93		13265512.34	2.65%	2.65%	Y	11.93	11.93
2	ACSITA 100 MG TABLET 10	ACSITA	ACMEDIX PHARMA LLP	100 MG	10	TABLET	49.29		52494.10	0.01%	0.01%	N	4.93	
3	SITAMAX 100 MG TABLET 10	SITAMAX	AJANTA PHARMA LTD	100 MG	10	TABLET	92.5		1913917.50	0.38%	0.38%	N	9.25	
4	SITAPRIL 100 MG TABLET 10	SITAPRIL	AJANTA PHARMA LTD	100 MG	10	TABLET	67.03		116028.93	0.02%	0.02%	N	6.70	
5	SITAPAZ 100 MG TABLET 10	SITAPAZ	AKESISS PHARMA (P) LTD	100 MG	10	TABLET	92.14		3434670.56	0.69%	0.69%	N	9.21	
6	SITALEMBIC 100 MG TABLET 15	SITALEMBIC	ALEMBIC LTD	100 MG	15	TABLET	149.07		11134831.23	2.23%	2.23%	Y	9.94	9.94
7	ALSITA 100 MG TABLET 10	ALSITA	ALKEM LABORATORIES LTD.	100 MG	10	TABLET	77.14		22426343.66	4.49%	4.49%	Y	7.71	7.71
8	SITALONG 100 MG TABLET 15	SITALONG	ALTEUS BIOGENICS PVT.LTD.	100 MG	15	TABLET	182.14		743131.20	0.15%	0.15%	N	12.14	
9	SITAGLIP 100 MG TABLET 10	SITAGLIP	ANTHEM BIOPHARMA PVT LTD	100 MG	10	TABLET	107.14		1658098.64	0.33%	0.33%	N	10.71	
10	SIDIA 100 MG TABLET 10	SIDIA	APRICA HEALTHCARE PVT LTD	100 MG	10	TABLET	107.14		1195789.54	0.24%	0.24%	N	10.71	
11	SITAGLO 100 MG TABLET 15	SITAGLO	ARISTO PHARMACEUTICALS PVT.LTD	100 MG	15	TABLET	171.43		19143073.81	3.83%	3.83%	Y	11.43	11.43
12	SITABEND 100 MG TABLET 10	SITABEND	BAL PHARMA	100 MG	10	TABLET	85.71		44397.78	0.01%	0.01%	N	8.57	
13	SITAPIL 100 MG TABLET 10	SITAPIL	CADELL HEALTH CARE PVT.LTD	100 MG	10	TABLET	142.14		200843.82	0.04%	0.04%	N	14.21	
14	JANKEY 100 MG TABLET 15	JANKEY	CADILA PHARMACEUTICALS LTD.	100 MG	15	TABLET	144.64		2084985.60	0.42%	0.42%	N	9.64	
15	SITENALI 100 MG TABLET 15	SITENALI	CADILA PHARMACEUTICALS LTD	100 MG	15	TABLET	144.64		1883212.80	0.38%	0.38%	N	9.64	
16	SITACIP 100 MG TABLET 10	SITACIP	CIPLA LTD.	100 MG	10	TABLET	92.14		15329423.94	3.07%	3.07%	Y	9.21	9.21
17	SITABITE 100 MG TABLET 10	SITABITE	CORONA	100 MG	10	TABLET	70.71		19010383.50	3.80%	3.80%	Y	7.07	7.07
18	STIG 100 MG TABLET 15	STIG	DR. REDOYS LABORATORIES LTD	100 MG	15	TABLET	117.86		8137761.56	1.63%	1.63%	Y	7.86	7.86
19	SITABET 100 MG TABLET 7	SITABET	EAST WEST PHARMA	100 MG	7	TABLET	88		31856.00	0.01%	0.01%	N	12.57	
20	SITADYL 100 MG TABLET 10	SITADYL	ELINOR PHARMA	100 MG	10	TABLET	128.57		71234.62	0.01%	0.01%	N	12.86	
21	EMSITA 100 MG TABLET 10	EMSITA	EMCURE PHARMACEUTICALS LTD	100 MG	10	TABLET	107.07		8834881.05	1.77%	1.77%	Y	10.71	10.71
22	GLURA 100 MG TABLET 10	GLURA	ERIS LIFESCIENCES LTD	100 MG	10	TABLET	107.14		27894113.28	5.58%	5.58%	Y	10.71	10.71
23	TERGRA 100 MG TABLET 10	TERGRA	ERIS LIFESCIENCES LTD	100 MG	10	TABLET	103.57		1757065.05	0.35%	0.35%	N	10.36	
24	SITDC 100 MG TABLET 10	SITDC	FDC LTD.	100 MG	10	TABLET	85.71		809530.95	0.16%	0.16%	N	8.57	
25	SITGLYPT 100 MG TABLET 15	SITGLYPT	FINECURE PHARMACEUTICALS	100 MG	15	TABLET	95.36		410429.44	0.08%	0.08%	N	6.36	
26	CTASORIN 100 MG TABLET 10	CTASORIN	FUSION HEALTHCARE PVT LTD	100 MG	10	TABLET	99.29		1742241.63	0.35%	0.35%	N	9.93	
27	SITAZIT 100 MG TABLET 10	SITAZIT	GLENMARK PHARMACEUTICALS LTD.	100 MG	10	TABLET	103.57		18498016.28	3.70%	3.70%	Y	10.36	10.36
28	QSITA 100 MG TABLET 10	QSITA	HBC LIFESCIENCES PVT LTD	100 MG	10	TABLET	57.14		5185854.98	1.04%	1.04%	Y	5.71	5.71
29	SITOZA 100 MG TABLET 10	SITOZA	HETERO HEALTHCARE LTD	100 MG	10	TABLET	82.14		1274479.17	0.25%	0.25%	N	8.21	
30	SPIKERID 100 MG TABLET 10	SPIKERID	INDICHEMIE HEALTH SPECIALITIES PVT. LTD.	100 MG	10	TABLET	70.71		130177.11	0.03%	0.03%	N	7.07	
31	SITARA 100 MG TABLET 10	SITARA	INTAS PHARMACEUTICALS LTD	100 MG	10	TABLET	96.43		32656212.36	6.53%	6.53%	Y	9.64	9.64
32	IGNALIS 100 MG TABLET 10	IGNALIS	INTAS PHARMACEUTICALS LTD	100 MG	10	TABLET	96.43		17210247.82	3.44%	3.44%	Y	9.64	9.64
33	SUITGLIP 100 MG TABLET 10	SUITGLIP	IPCA LABORATORIES PVT LTD.	100 MG	10	TABLET	85.71		1162913.28	0.23%	0.23%	N	8.57	
34	JSITA 100 MG TABLET 10	JSITA	JARUN PHARMACEUTICALS	100 MG	10	TABLET	92.14		98497.66	0.02%	0.02%	N	9.21	
35	SITACOSE 100 MG TABLET 10	SITACOSE	JB CHEMICALS	100 MG	10	TABLET	85.72		2653548.32	0.53%	0.53%	N	8.57	
36	SITAHENZ 100 MG TABLET 10	SITAHENZ	LA RENON	100 MG	10	TABLET	105.71		21018002.17	4.21%	4.21%	Y	10.57	10.57
37	SUGARAY 100 MG TABLET 15	SUGARAY	LLOYD HEALTHCARE PVT.LTD	100 MG	15	TABLET	127.5		2806912.50	0.56%	0.56%	N	8.50	
38	LUPISIT 100 MG TABLET 10	LUPISIT	LUPIN LTD	100 MG	10	TABLET	85.71		18035526.75	3.61%	3.61%	Y	8.57	8.57

39	SITA OD 100 MG TABLET 10	SITA OD	MACLEODS PHARMACEUTICALS PVT.LTD	100 MG	10	TABLET	75.71	26094435.73	5.22%	5.22%	Y	7.57	7.57
40	SITACLESS 100 MG TABLET 10	SITACLESS	MACLEODS PHARMACEUTICALS PVT.LTD	100 MG	10	TABLET	75.71	1991892.07	0.39%	0.39%	N	7.57	
41	MACSITA 100 MG TABLET 10	MACSITA	MACLEODS PHARMACEUTICALS PVT.LTD	100 MG	10	TABLET	75.71	12182798.94	2.44%	2.44%	Y	7.57	7.57
42	SITADAY 100 MG TABLET 15	SITADAY	MANKIND PHARMACEUTICALS LTD.	100 MG	15	TABLET	148.93	21583382.39	4.32%	4.32%	Y	9.93	9.93
43	CORSITA 100 MG TABLET 10	CORSITA	MEDLEY PHARMACEUTICALS	100 MG	10	TABLET	113.57	4271708.41	0.85%	0.85%	N	11.36	
44	SITANORM 100 MG TABLET 15	SITANORM	MICRO LABS LTD	100 MG	15	TABLET	127.86	11919364.92	2.38%	2.38%	Y	8.52	8.52
45	SITAPRIDE 100 MG TABLET 15	SITAPRIDE	MICRO LABS LTD	100 MG	15	TABLET	127.86	15022654.98	3.01%	3.01%	Y	8.52	8.52
46	SITATUF 100 MG TABLET 10	SITATUF	MOREPEN LABORATORIES LIMITED	100 MG	10	TABLET	105.71	60571.83	0.01%	0.01%	N	10.57	
47	JANUVIA 100 MG TABLET 15	JANUVIA	MSD PHARMACEUTICALS PRIVATE LTD.	100 MG	15	TABLET	192.86						
48	JANUVIA 100 MG TABLET 7	JANUVIA	MSD PHARMACEUTICALS PRIVATE LTD.	100 MG	7	TABLET	192.86						
49	SITA (MSN) 100 MG TABLET 10	SITA (MSN)	MSN LABORATORIES LTD	100 MG	10	TABLET	99.29	2492874.03	0.50%	0.50%	N	9.93	
50	SITANAT 100 MG TABLET 10	SITANAT	NATCO PHARMA LTD	100 MG	10	TABLET	113.57	2490476.53	0.50%	0.50%	N	11.36	
51	GLIPCRIN 100 MG TABLET 15	GLIPCRIN	PRIMUS REMEDIES PVT LTD	100 MG	15	TABLET	138.75	2283131.25	0.46%	0.46%	N	9.25	
52	GLIPTASAN 100 MG TABLET 7	GLIPTASAN	SANATRA HEALTH CARE PVT.LTD	100 MG	7	TABLET	140	118580.00	0.02%	0.02%	N	20.00	
53	6F1C 100 MG TABLET 15	6F1C	SINSAN PHARMACEUTICALS	100 MG	15	TABLET	250	356500.00	0.07%	0.07%	N	16.67	
54	SITASPEC 100 MG TABLET 7	SITASPEC	SPECTRA THERAPEUTICS PVT. LTD.	100 MG	7	TABLET	78.58	347480.76	0.07%	0.07%	N	11.23	
55	ISTAVEL 100 MG TABLET 10	ISTAVEL	SUN PHARMA LABORATORIES LTD.	100 MG	10	TABLET	92.5						
56	ISTAVEL 100 MG TABLET 7	ISTAVEL	SUN PHARMA LABORATORIES LTD.	100 MG	7	TABLET	64.75						
57	SITARED 100 MG TABLET 10	SITARED	SUN PHARMA LABORATORIES LTD.	100 MG	10	TABLET	64.75						
58	SITARED 100 MG TABLET 7	SITARED	SUN PHARMA LABORATORIES LTD.	100 MG	7	TABLET	64.75						
59	SITASYS 100 MG TABLET 10	SITASYS	SYSTOPIC LABORATORIES LTD-MEM	100 MG	10	TABLET	56.43	4642207.94	0.93%	0.93%	N	5.64	
60	SITALENT 100 MG TABLET 10	SITALENT	TALENT INDIA	100 MG	10	TABLET	127.86	404293.32	0.08%	0.08%	N	12.79	
61	SITABEST 100 MG TABLET 10	SITABEST	TAS MED (INDIA) PRIVATE LTD.	100 MG	10	TABLET	92.86	169098.06	0.03%	0.03%	N	9.29	
62	SITAXA 100 MG TABLET 15	SITAXA	TORRENT PHARMACEUTICALS LTD.	100 MG	15	TABLET	159.64	37728838.68	7.55%	7.55%	Y	10.64	10.64
63	STALIX 100 MG TABLET 15	STALIX	TORRENT PHARMACEUTICALS LTD.	100 MG	15	TABLET	159.64	31711368.52	6.34%	6.34%	Y	10.64	10.64
64	SITASON 100 MG TABLET 10	SITASON	UNISON PHARMACEUTICALS	100 MG	10	TABLET	46.43	1631968.07	0.33%	0.33%	N	4.64	
65	SITAWOK 100 MG TABLET 15	SITAWOK	WOCKHARDT LTD	100 MG	15	TABLET	85.61	8939567.42	1.78%	1.78%	Y	5.71	5.71
66	SITASAR 100 MG TABLET 10	SITASAR	WONSET HEALTH CARE PRIVATE LIMITED	100 MG	10	TABLET	92.86	277372.82	0.06%	0.06%	N	9.29	
67	ZENSITA 100 MG TABLET 10	ZENSITA	ZUVENTUS HEALTHCARE LTD	100 MG	10	TABLET	92.5	2457540.00	0.49%	0.49%	N	9.25	
68	SIGLYN 100 MG TABLET 10	SIGLYN	ZYDUS CADILA - ZHL	100 MG	10	TABLET	107.14	16202889.34	3.24%	3.24%	Y	10.71	10.71
69	SITAGLYN 100 MG TABLET 10	SITAGLYN	ZYDUS CADILA - ZHL	100 MG	10	TABLET	107.14	10437471.66	2.09%	2.09%	Y	10.71	10.71
		Rs. Per tablet											
	Worked out Retail Price	10.74	Excluding GST										

Note: In view of DPCO Amendment Vide S.O. No. 2165(E) dated 11.05.2023, Patent Holder of Sitagliptin Le. M/s MSD Pharmaceuticals Private Ltd & License holder Le. M/s Sun Pharma is not considered for price fixation.